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Abstract 
             (−)-Aphanorphine is an alkaloid isolated from the fresh water algae 
Aphanizomenon flos-aquae. The 3-benzazepine scaffold in aphanorphine resembles the 
benzomorphan analgesics such as pentazocine, eptazocine and morphine. The complex 3-
benzazepine scaffold and a quaternary stereocenter has made (−)-aphanorphine an 
interesting synthetic target. The synthesis of (−)-aphanorphine from an enantiomerically 
enriched α-hydroxy acid derivative is described in Chapter 1 of this thesis. This hydroxy 
acid is readily available from an ephedrine-derived morpholinone via a highly 
diastereoselective allylation followed by removal of the ephedrine portion. The 
methodology developed for the synthesis of (−)-aphanorphine is potentially useful for the 
synthesis of other N-methylpyrrolidine-based natural products and related structural 
motifs.  
Clauslactone S is a terpenoid which was extracted from the leaves and stems of 
Clausena excavate in 2008. There has been no synthesis of clauslactone S reported to 
date. We envisaged that the substituted δ-lactone in clauslactone S can be synthesized 
using an enantiomerically enriched α-hydroxy acid derivative. Studies on the 
development of a modular synthetic strategy for clauslactone S and the details of the 
synthesis of a potential intermediate to clauslactone S are described in Chapter 2 of the 
thesis. 
The α-hydroxy acid derivative employed as starting material in the aphanorphine 
and clauslctone S studies is readily obtained by a highly diastereoselective double 
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alkylation of an ephedrine-derived morpholinedione. However, the limitation of the 
methodology is that ephedrine is no longer commercially available. Hence, studies were 
conducted on several morpholinediones, that were derived from enantiomerically 
enriched amino alcohols, with the objective of finding an alternative to ephedrine. Details 
of these investigations are presented in Chapter 3 of this thesis. 
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Formal Total Synthesis of (−)-Aphanorphine 
 
 
 
 
This chapter is based on the following publication: 
Pansare, S. V.; Kulkarni, K. G. RSC Advances 2013, 3, 19127. 
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1.1 Introduction to (−)-aphanorphine: 
Aphanorphine (1) is an alkaloid isolated from a fresh water algae Aphanizomenon 
flos-aquae by Shimizu and Clardy.1 It shares common structural features with the 
analgesic benzomorphan alkaloids eptazocine (2), pentazocine (3), and morphine (4, 
Figure 1). The 3-benzazepine ring system and a quaternary stereocenter has made 
aphanorphine an interesting synthetic target. Over the last two decades, research 
groups around the globe have reported the synthesis of aphanorphine. The first 
enantioselective synthesis of (+) and (−)-aphanorphine was reported by Takano and 
co-workers.2 Some of the notable syntheses in the last decade are presented in the 
following discussion. 
 
Figure 1.1 Structural similarity of (−)-aphanorphine with benzomorphan alkaloids. 
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1.2 Known synthetic routes to aphanorphine  
1.2.1 Syntheses of aphanorphine using natural amino acids as starting materials: 
The Ishibashi group3 accomplished the synthesis of (−)-aphanorphine using 
(2S,4R)-4-hydroxyproline (5) as a chiral starting material. An aryl radical cyclization 
was used as the key step to obtain an important precursor 10. Acid-catalyzed 
esterification, amine protection with benzyl chloroformate and silylation of the 
hydroxyl group in 5 provided 6 as reported earlier.4 Alkylation of the lithium enolate 
of 6 afforded 7 as a 4:1 mixture of diastereomers. Removal of the silyl protection in 7 
followed by recrystallization of the secondary alcohol provided 8 as a single 
diastereomer. Oxidation of 8 using pyridinium chlorochromate, followed by a Horner-
Wittig reaction of the resulting ketone with the lithium salt of PhSCH2P(O)Ph25 in the 
presence of CeCl3, followed by treatment of the adduct with NaH afforded the radical 
precursor 9 (Scheme 1.1). 
 
Scheme 1.1 
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Treatment of 9 with Bu3SnH and AIBN in refluxing benzene accomplished a 
6-exo cyclization of the aryl radical onto the vinyl sulfide to provide a tricyclic 
intermediate. An alkaline hydrolysis of the ester group produced the acid 10 in 
quantitative yield. Condensation of 10 with 2-mercaptopyridine N-oxide and treatment 
with Bu3SnH and AIBN provided the decarboxylation product 12. Treatment of 12 
with Raney nickel in hot methanol accomplished the following three steps; 
desulfurization, removal of the benzyloxycarbonyl group and reductive amination to 
furnish the amine 14. O-Demethylation in 14 (65%), using BBr3, accomplished the 
total synthesis of (−)-aphanorphine 1 (Scheme 1.2) with 7.6% overall yield from 6. 
Scheme 1.2 
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The Zhai group reported a formal total synthesis of (−)-aphanorphine starting 
from (2S,4R)-4-hydroxyproline (5).6 A four-step reaction sequence reported earlier by 
Westwood and Walker7 was employed to afford 15 from 4-hydroxyproline (5) in 72% 
yield.7 Swern oxidation of 15 afforded the corresponding aldehyde, which upon 
treatment with 4-methoxyphenylmagnesium bromide furnished 16 as a 3:2 mixture of 
diastereomers. Reductive dehydroxylation of 16 using triethylsilane and BF3.OEt2 and 
concomitant desilylation afforded the corresponding pyrrolidinol, which was oxidized 
to the pyrrolidinone 17 under Swern oxidation conditions. Methymagnesium iodide 
was added to ketone 17 to obtain tertiary alcohol 18 as a mixture of diastereomers 
(18a:18b = 4:1). Friedel-Crafts cyclization of 18 in the presence of AlCl3 afforded the 
desired intermediate 19. This concluded the formal synthesis of (−)-aphanorphine 1 
(Scheme 1.3). An important feature of this synthesis is the simultaneous construction 
of the central six-membered ring and the quaternary stereocenter. 
 
Scheme 1.3 
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The Zhai group also reported the synthesis of unnatural (+)-aphanorphine 
using (2S,4R)-4-hydroxyproline (5)6b,8 as the starting material. In order to use the 
earlier approach6b discussed in Scheme 1.3 for the synthesis of (+)-aphanorphine, 
inversion of configuration at C-2 in 5 was required (Scheme 1.4). This was achieved 
over three steps. N-Benzoylation9 of 5, followed by heating in acetic anhydride 
furnished the lactonization product 21 with inversion of configuration at the C-2 
stereocenter.10 Treatment of a mixture of 21 and Me(OMe)NH.HCl with                            
p-methoxyphenylmagnesium bromide afforded the pyrrolidinone 23. This conversion 
also resulted in the formation of the corresponding Weinreb amide 22, which can be 
converted to 23 by further treatment with p-methoxyphenylmagnesium bromide.  The 
ketone in 23 was reduced to provide 25 (Scheme 1.4) by 1,3-dithiolane formation and 
desulfurization with Bu3SnH, AIBN. The inversion of stereochemistry at C-2 in 25 
was confirmed using NOESY.  
 
Scheme 1.4. 
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Swern oxidation of 25 furnished a pyrrolidinone, which on addition of 
methyllithium afforded the tertiary alcohol 26. Friedel-Crafts cyclization of 26 
furnished the tricyclic intermediate 27 as a single diastereomer. Basic hydrolysis of 
27, followed by treatment with formalin and sodium cyanoborohydride furnished       
(−)-8-O-methylaphanorphine 28 (71% over two steps and 17% overall yield Scheme 
1.5). 
 
Scheme 1.5 
Li and co-workers utilized Boc-D-tyrosine 29 as the chiral starting material for 
the synthesis of (−)-aphanorphine.11 Unlike the syntheses discussed earlier, the central 
6-membered ring in aphanorphine was constructed first, followed by formation of the 
pyrrolidine ring. Weinreb amide 30 was obtained from the coupling of Boc-D-tyrosine 
and N,O-dimethylhydroxylamine.  N-Methylation of 30 followed by treatment with 
the enolate of 2-(trimethylsilyl)ethyl acetate furnished the chain-extended product 31. 
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Azidation of 31 with Hunig’s base and tosylazide and subsequent cyclization using 
rhodium acetate provided 32 (78%). Diastereoselective methylation of 32 using 50% 
KOH and MeI, in the presence of cinchona-derived ammonium salt 33, furnished 34 
as a mixture of diastereomers (34a:34b = 12:1, Scheme 1.6).  
Scheme 1.6 
Acid catalyzed deprotection of the major diastereomer of 34 provided the 
corresponding amino acid which was cyclized to provide the lactam 35 (Scheme 1.7). 
Conversion of the ketone to a thioketal, followed by LiAlH4 reduction gave                                   
(+)-8-O-aphanorphine 14. Boron tribromide mediated O-demethylation in 14 
furnished (−)-aphanorphine 1 with 22% overall yield (Scheme 1.7).  
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Scheme 1.7 
The Zhai group reported12 a synthesis of (−)-aphanorphine using O-methyl-D-
tyrosine methyl ester hydrochloride salt (37), prepared from D-tyrosine (36) as the 
starting material (Scheme 1.8) according to the previously reported procedure13. 
Unlike the synthesis shown in Schemes 1.6 and 1.7,11 the pyrrolidine ring was 
constructed first followed by the synthesis of the central six membered ring.                     
N-Tosylation and N-propargylation of 37 furnished 38 in 93% yield over two steps. 
The ester group in 38 was reduced to an alcohol which, upon treatment with I2, PPh3, 
and imidazole, afforded 39. The treatment of 39 with In and I2 in DMF furnished the 
alkene 40. AlCl3 mediated cyclization of 40 formed the tricyclic structure of (−)-
aphanorphine as a single diastereomer 19 (Scheme 1.8). This concluded the formal 
synthesis of (−)-aphanorphine 1. Conversion of 19 into (−)-aphanorphine 1 was 
previously accomplished over three steps.14 
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Scheme 1.8 
1.2.2 Synthesis of aphanorphine using substituted aromatic substrates as      
            starting materials: 
The Zhai group has also reported 14 a second approach for the synthesis of         
(−)-aphanorphine 1 using 4-methoxyphenylacetaldehyde 41 as the starting material. In 
this approach as well, the pyrrolidine ring was constructed first, followed by the six-
membered ring. The homoallylic alcohol 43 (95% ee) was prepared by treatment of 
41 with the diisopinocampheyl(methallyl)borane reagent 42 in ether (prepared from 
methallylmagnesium chloride and (+)-DIP-chloride).15 The alcohol 43 was further 
treated with TBHP in the presence of 2 mol% VO(acac)2 to give epoxy alcohol 44 as 
a mixture of diastereomers (44a:44b = 2:1). Conversion of 44 to epoxy azide 45 was 
done by the treatment of 44 with HN3, PPh3, and DEAD in benzene. Chemoselective 
11 
 
azide reduction (without affecting the epoxide group), was done using hydrogen in the 
presence of the Lindlar catalyst. The resulting amines were tosylated to obtain 46a and 
46b (Scheme 1.9) which were separated by chromatography. The sulfonamide 46b 
was used further. 
Scheme 1.9 
Deprotonation of 46b and cyclization of the tosyl amide anion onto the epoxide 
provided 18. Construction of the aphanorphine framework 19 was accomplished by 
using AlCl3-mediated Friedel-Crafts cyclization of 18 in good yield (88%). 
Detosylation of 19 with Red-Al and subsequent N-methylation with formaldehyde and 
NaBH3CN accomplished the synthesis of (+)-8-O-methylaphanorphine 14 (Scheme 
1.10). This concluded the formal total synthesis of (−)-aphanorphine 11.  
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Scheme 1.10 
Gallagher and co-workers reported a synthesis of (−)-aphanorphine using            
2-bromoanisaldehyde 47 as a starting material.16 A cyclic sulfimidate 54 was utilized 
as the key precursor for the pyrrolidine ring in the target (Scheme 1.11). Synthesis of 
54 started with reaction of 2-bromoanisaldehyde with phosphonate 48 and 
tetramethylguanidine (TMG) to provide 49 which was subjected to asymmetric 
hydrogenation with Rh(DuPHOS)17 to provide the amino ester 51 with excellent 
enantioselectivity (99% ee). Reduction of 51 with LiAlH4 at 0 °C provided the amino 
alcohol 52. The alcohol 52 was subjected to a one pot process of in situ N-methylation 
and hydrolysis of the Boc carbamate to obtain 53 in excellent yield (99%). Amino 
alcohol 53 was treated with thionyl chloride to obtain a cyclic sulfamidite which was 
oxidized to the sulfamidate 54 by RuCl3/NaIO4 mediated oxidation.18 
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Scheme 1.11 
The sulfamidate 54 was then treated with triethyl phosphonoacetate and t-
BuOK and the resulting cyclic phosphonate was converted to 55 by Wadsworth-
Emmons olefination using formaldehyde (Scheme 1.12). Bu3SnH and AIBN-mediated 
radical cyclization of 55 furnished 56. At this point, construction of the cyclic 
framework for (−)-aphanorphine with desired stereochemistry was achieved. 
Reduction of the amide in 56 followed by O-demethylation afforded (−)-aphanorphine 
1 with 20.1% overall yield. 
14 
 
 
Scheme 1.12 
Funk and co-workers reported a concise synthesis of (±)-aphanorphine 62 
using the 5-amido-1,3-dioxine 59 as a starting material.19 Acid chloride 57 was treated 
with N-methylimine 58 to afford 59 (Scheme 1.13). The treatment of 59 with MeAlCl2 
resulted in an intramolecular aromatic substitution reaction to furnish aldehyde 60 as 
a single (trans) diastereomer which was reduced to alcohol 61 using NaBH4.  
Mesylation of 61 followed by cyclization afforded the bridged bicyclic lactam 56. 
Lactam reduction with LiAlH4 and O-demethylation using BBr3 resulted in the 
formation of (±)-aphanorphine 62 with 15% overall yield (Scheme 1.13). 
 
 
15 
 
Scheme 1.13 
1.2.3 Synthesis of (+) and (−)-aphanorphine using a chiral sulfinamide starting    
           material: 
Foubelo and co-workers reported a synthesis of (−)-aphanorphine as well as 
(+)-aphanorphine using 4-methoxyphenylacetaldehyde as the starting material.20 
Indium-mediated one-pot α-amino allylation of 63 using (R)-2-methylpropane-2-
sulfinamide 64 and methallyl bromide afforded 65 with high diastereoselectivity (dr 
93:7). Epoxidation of 65 using m-CPBA furnished 66 as a 1.2:1 mixture of 
diastereomers. Treatment of 66 with KI and K2CO3 gave 67 by cyclization of an 
intermediate primary iodide (Scheme 1.14). 
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Scheme 1.14 
  Attempted Friedel-Crafts cyclization of 67 resulted in decomposition under 
various conditions. Changing the N-protection to a benzoyl group was beneficial and 
the Friedel-Crafts cyclization of 68 furnished 69 as a single diastereomer. Hydrolysis 
of the benzamide in 69 followed by N-methylation provided (+)-8-O-methyl 
aphanorphine 14. BBr3-mediated O-de-methylation furnished (−)-aphanorphine 1 
(Scheme 1.15). Similarly, (+)-1 was prepared using the S enantiomer of sulfinamide 
64 as the chiral reagent.  
 
 
 
 
17 
 
 
Scheme 1.15 
 Grainger and co-workers also reported a synthesis of (−)-aphanorphine using 
(R)-t-butanesulfinamide 64 as a chiral starting material (Scheme 1.16).21 A 
photochemical radical reaction of a dithiocarbamate was used as a key reaction in the 
synthesis. (R)-t-butanesulfinamide 64 was condensed with (E)-4-heptenal 70 to afford 
(E)-sulfinimine 71. Methallylmagnesium chloride was added to 71 to provide 
sulfonamide 72 as a 5:1 mixture of diastereomers. The configuration of the major 
isomer was assigned as R based on the Ellman model for nucleophilic addition to chiral 
sulfinimines such as 71.22 The diastereomeric mixture was carried forward without 
purification. N-methylation of 72 was carried out using n-BuLi and MeI and the 
resulting 1,7-diene 73 was subjected to ring-closing metathesis using the Grubbs 
second generation catalyst to obtain 74 in excellent yield (94%, Scheme 1.16). The 
sulfinyl portion was removed using 4 M HCl to provide the salt 75.  
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Scheme 1.16 
The hydrochloride salt 75 was treated with carbonyldiimidazole 76 and K2CO3 
to obtain carbamoylimidazole 77 in quantitative yield. N-methylation of 77 gave the 
corresponding carbamoyl imidazolium salt,23 which upon reaction with sodium 
diethylthiocarbamate provided the radical cyclization precursor 78 (86% yield over 
two steps). The photochemical radical cyclization of 78 gave 79 in 71% yield (Scheme 
1.17). The structure of 79 was confirmed by X-ray crystallography.  
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Scheme 1.17 
Treatment of 79 with TEMPO under irradiation using a mercury lamp replaced 
the carbon-sulfur bond with a carbon-oxygen bond to afford 80 with retention of 
configuration (Scheme 1.18). Oxidation of 80 using m-CPBA resulted in formation of 
ketone 81.  Reaction of 81 with dimethyl 2-(methoxymethylene)malonate 82 under the 
basic conditions followed by acid-catalyzed cyclization resulted in the formation of 
the pyrone 83. An inverse-electron-demand Diels-Alder reaction of 83 with                          
1,1-dimethoxyethene, followed by loss of CO2 and methanol from the cycloadduct 84, 
resulted in the formation of the required tricyclic ring system 85. Hydrolysis of the 
ester to an acid, followed by copper-mediated decarboxylation provided 56 (Scheme 
1.18). LiAlH4 reduction of 56 and BBr3 mediated O-demethylation provided                 
(−)-aphanorphine 1.  
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Scheme 1.18 
1.2.4 Synthesis of (+)-aphanorphine employing asymmetric alkene 
carboamination: 
Wolfe reported the enantioconvergent synthesis of unnatural (+)-aphanorphine 
using a racemic precursor (±)-88.24 The synthesis of 88 started from N-boc-1-amino-
2-propanol 86. Oxidation of 86 to a ketone followed by reaction with allyl magnesium 
bromide provided 87. The silyl protection of 87 was done using TMS-imidazole to 
obtain the precursor (±)-88 in 91% yield (Scheme 1.19). 
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Scheme 1.19 
The coupling of 88 with 4-bromoanisole with  concomitant ring formation was 
carried out using a palladium catalyst in the presence of a chiral ligand ((R)-Siphos-
PE), to provide a 1:1 mixture of pyrrolidines 89a and 89b. Removal of the Boc group 
using TFA and tosylation of the resulting amine provided 90 (1:1 dr). AlCl3-mediated 
Friedel-Crafts cyclization of 90 furnished 91 (81% ee, Scheme 1.20). 
 
Scheme 1.20 
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The tosyl group in 91 was removed using Red-Al and the resulting amine was 
treated with formalin and formic acid to obtain 28 (Scheme 1.21). BBr3 mediated                         
O-demethylation provided (+)-aphanorphine (ent-1, Scheme 1.21). 
Scheme 1.21 
1.3 Present work: 
1.3.1 An enantioselective approach to (−)-aphanorphine employing a chiral               
         α-hydroxy acid as the starting material 
The Pansare group has been involved in the synthesis of α-alkyl,α-hydroxy 
acid derivatives as intermediates in the synthesis of biologically relevant motifs and 
natural products.25 In the present study, a synthesis of (−)-aphanorphine was 
envisioned based on the α-hydroxy acid derivative 94 as a starting material (Scheme 
1.22). The synthetic strategy involves Friedel-Crafts cyclization of 92 for the synthesis 
of a central six membered ring as in previous aphanorphine syntheses.14,20,24 A 
stereoselective C-N bond formation is used in the synthesis of the key pyrrolidine 
intermediate 92. The precursor to this pyrrolidine is the hydroxy amide 93 which is 
obtained from an enantiomerically enriched α-hydroxy pentenoic acid derivative 94 
by a cross metathesis reaction. The amide 94 can be obtained by the asymmetric 
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allylation of a chiral pyruvic acid derivative obtained by amidation with (1R,2S)-
ephedrine (97).  
 
Scheme 1.22 Synthetic strategy for the synthesis of (+)-8-O-methylaphanorphine 14. 
 The initial approach was aimed at the synthesis of an N-methyl pyrrolidinone 
as a precursor to the pyrrolidine motif in aphanorphine. This approach was attractive 
for two reasons: 1) several substituted N-methylpyrrolidinones are natural products26 
or  structural motifs in bioactive molecules27 and the present study could potentially 
provide a methodology for their synthesis as well; and 2) the starting material for the 
pyrrolidinone based approach, the α-hydroxy N-methyl amide (R)-9428 could be 
directly obtained by asymmetric allylation of an ephedrine-derived chiral pyruvamide 
developed in the Pansare group.28 When the aphanorphine synthesis was first initiated, 
a gram-scale synthesis of 95 was required. This required a scale-up of the existing 
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synthesis of 95 developed earlier in the Pansare group.28 In the interest of time, while 
the scale-up was being optimized, alternate methods were also examined for the 
synthesis of 94 via the corresponding acid 102 (Scheme 1.23). 
Initially, the asymmetric allylation of a 1,3-dioxolanone, derived from              
(S)-lactic acid and pivalaldehyde, as described by Seebach29 was investigated. 
Accordingly, the treatment of (S)-lactic acid 98 with pivalaldehyde, p-TsOH and 
catalytic amount of H2SO4 in refluxing pentane provided 99 as a 4:1 mixture of 
diastereomers. Pure cis-99 (75%) was obtained by recrystallization from 
ether/pentane, and then was treated with LDA at −78 °C in THF/hexane (9:1), followed 
by addition of allyl bromide to obtain 100 in poor yields (27-32%). Similarly, 101 was 
obtained by alkylation of the anion with the 4-methoxycinnamyl bromide in low yields 
(18-30%, Scheme 1.23) after several attempts. However, the attempted hydrolysis of 
100 and 101 to the acids 102 and 103 respectively, using KOH resulted in complex 
mixtures. This approach was therefore not pursued further. 
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Scheme 1.23 
The synthesis of the required α-hydroxy acid was next attempted by the 
asymmetric allylation of benzyl pyruvate, as reported by Mukaiyama.30 A divalent 
tin(II) catecholate 104 was treated with allyl bromide in the presence of (+)-
diisopropyl tartrate, DBU and a catalytic amount of CuI to obtain the allylating reagent 
105. Treatment of benzyl pyruvate with 105 furnished 106 in 65% yield, but with poor 
enantioselectivity (25 and 27% ee, Scheme 1.24). This approach was therefore also 
not pursued further. 
Scheme 1.24 
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At this point, it was obvious that the ephedrine-based methodology needed to 
be optimized28 to synthesize 94 in gram quantities (Scheme 1.25). During these 
studies, it was noticed that the use of TiCl4 as the Lewis acid for the allylation step 
worked well only on a millimolar scale. For gram-scale allylation of 107, the use of 
BF3.OEt2 instead of TiCl4, provides 95 with excellent diastereoselectivity. An added 
advantage is that while the TiCl4 reaction has to be conducted at −78 °C, the BF3.OEt2 
-mediated allylation can be conducted at ambient temperature. With the modified 
procedure, up to 2.0 g of 94 can be routinely prepared from ephedrine and pyruvic acid 
in two days.31 
 
Scheme 1.25 
The initial aim of this study was to perform a halolactamization reaction of 94 
to provide the functionalized pyrrolidinone 109 as a key intermediate to aphanorphine. 
A variety of conditions that are reported to promote halolactamization of secondary 
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amides were screened and the results of these experiments are summarized in Table 1. 
In some of these reactions, the iodohydrin 109 was also obtained as a byproduct. 
Table 1.1 Iodolactamization studies with 94. 
 
No. Reagents Solvent Results 
1 NaHCO3, I2, CH3CN 109 a 
2 NIS, NaOH MeOH + Dioxane 109 + lactone + 94 
3 DMS(OTf)2, Et3N, I2 CH2Cl2 No isolable product 
4 DMS(OTf)2, Et3N, ICl CH2Cl2 No isolable product 
5 n-BuLi, TMSOTf, I2 THF 94b 
6 Et3N, TMSOTf, 
 Br bis(collidine)2 OTf 
CH2Cl2 94 
a: reaction was carried out at 0 °C. b: reaction was warmed gradually from -78 °C to 
room temperature 
In addition, intramolecular amidomercuration/halogenation32 reactions of 94 
were also attempted. None of these reactions however provided any of the required 
lactam. The results of these studies are summarized in Table 2. 
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Table 1.2 Amidomercuration conditions for the attempted lactamization of 94 
 
Entry Reagents T (h) Result 
1 Hg(OAc)2, KI, I2  20 Complex reaction mixture 
2 Hg(CF3CO2)2, KI  24 94 
3 Et3N, TMSOTf, 
Hg(OAc)2 
 24 Complex reaction mixture 
4 Et3N, TMSOTf, 
Hg(CF3CO2)2, KBr, 
NaHCO3 
 24 Silylation 
 
Finally, under the iodolactamization conditions reported by Knapp,33 
(treatment of 94 with TMSOTf, which presumably forms the O-silylimidate 110, 
followed by addition of iodine) provided 108 in good yield (84%) but with poor 
diastereoselectivity (1.6:1 dr, Scheme 1.26). The hydroxyl group34 in 108 was 
protected as a TBDMS ether using TBDMSOTf and Et3N to obtain 111. The next 
objective was to convert 111 to the pyrrolidine 112, which is an advanced precursor 
to aphanorphine. Accordingly, cross coupling reactions of 111 and 4-bromoanisole 
were investigated (Scheme 1.26). The conditions reported by Fu35 (treatment with 
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NiI2, trans-2-aminocyclohexanol and p-anisylboronic acid in i-PrOH) resulted in the 
formation of a complex mixture of products. The treatment of 111 with TMEDA, 
FeCl3, and p-anisylmagnesium bromide, according to the conditions reported by 
Bedford,36 resulted only in recovery of unreacted starting material.  
Scheme 1.26 
As an alternative, the halolactamization of a suitably substituted pentenamide 
as a more direct approach to 112 was investigated. It may be noted that the direct 
halolactamization of 5-aryl-4-pentenamides has not previously been reported. To 
examine this possibility, amide 94 was subjected to a cross-metathesis37 reaction with 
4-vinyl anisole using the Grubbs II catalyst. Although this reaction appeared to 
succeed, separation of the desired product from the stilbene byproduct (obtained from 
the homocoupling of 4-vinyl- anisole) was extremely difficult. Hence, 94 was 
converted38 to the acid 102 which was then subjected to a cross-metathesis37 reaction 
with 4-vinylanisole using the Grubbs II catalyst to provide the trans-pentenoic acid 
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103. The acid 103 could be easily separated from the stilbene by-product by extraction 
with aqueous sodium bicarbonate. Amidation of 103 with methylamine provided 93. 
Unfortunately, reactions of 93 under a variety of halolactamization conditions, 
including the Knapp procedure, resulted only in complex mixtures (Scheme 1.27). 
 
Scheme 1.27 
 Clearly, an alternative lactamization strategy was necessary and a nitrenium 
ion-mediated strategy39 was explored. To pursue this approach, acid 103 was 
converted to N-methoxy amide 114 under standard conditions (Scheme 1.28). 
Oxidative ring closure of the crude N-methoxy amide, employing 
bis(trifluoroacetoxy)iodobenzene40 and in situ hydrolysis of the resulting benzylic 
trifluoroacetate41 resulted in the formation of  hydroxypyrrolidine 119 as 5:1 mixture 
of diastereomers.  
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Scheme 1.28 
Following the proposed41 mechanism for such reactions, it is plausible that the 
cyclization begins with the formation of N-methoxy-N-trifluoroacetoxy amide 115, 
which reacts with the alkene to form the intermediate 116. Reaction of 116 with 
trifluoroacetate anion provides the pyrrolidinone 117. Basic hydrolysis of 117 results 
in the formation of 118 as a 5:1 mixture of diastereomers. At this stage, it was unclear 
if this diastereomeric mixture was obtained due to unselective C-N bond formation or 
due to the unselective capture of an intermediate benzylic cation by trifluoroacetate. 
Gratifyingly, subsequent reduction of 118 with triethylsilane yielded the pyrrolidinone 
119 as a single diastereomer (Scheme 1.29). This indicated that the C-N bond 
formation step was highly stereoselective. The existing stereocenter in 114 presumably 
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plays an important role in the stereoselective C-N bond formation to provide 119. The 
high stereoselectivity for the formation of 119 is contradictory to the moderate 
diastereoselectivity observed in the iodine (III) mediated cyclization of N-para-
met5hoxyphenyl-2-benzyl-4-pentenamides.42 The reasons for the formation of only 
119, and not the corresponding diastereomer, are not clear at present. 
Reduction of  the N-O bond in 119 was tested under the conditions previously 
used in the Pansare group such as Zn/AcOH43 at 50 °C or  In/NH4Cl.44 It was observed 
that the N-O bond in 119 is inert to these methods. However, treatment of 119 with 
Mo(CO)641 in refluxing CH3CN effectively reduced the N-O bond to provide 120. The 
pyrrolidinone 120 was reduced with LiAlH4 to provide the key pyrrolidine 121 which 
was tosylated to provide 122 (Scheme 1.29). The cis orientation of the CH3 and CH2Ar 
groups in 121 (3R,5R) was confirmed by comparison of the spectroscopic data for the 
pyrrolidine 121 with data reported for a mixture of (3S,5R) and (3S,5S) 121 and that 
for (3R,5S) 121.20  
 
Scheme 1.29 
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Establishment of the stereochemistry of the oxidative amidation step, and 
hence the absolute configuration of the pyrrolidinone 120, was done by conversion of 
tosylamide 122 to the known benzomorphan derivative (−)-19 (91% ee, Scheme 1.30) 
which has been previously converted to (−)-aphanorphine. Comparison of the optical 
rotation of 19 ([α]D25 −18.9 (c 0.9, CHCl3)) with the reported12 value for (1R,4S)-19 
([α]D25 −16.9 (c 0.89, CHCl3)) confirmed the absolute stereochemistry for 19. This also 
confirmed the absolute configuration of 120 and hence that of 121. N-formylation of 
121 with acetic formic anhydride furnished the corresponding N-formyl derivative, 
and AlCl3-mediated intramolecular Friedel-Crafts cyclization to provide the 
benzomorphan 123 (Scheme 1.30). Reduction of the formamide in 123 with LiAlH4 
afforded (+)-8-O-methylaphanorphine 14 (Scheme 1.30). This completed the formal 
synthesis of (−)-aphanorphine 1 since the conversion of 14 to (−)-aphanorphine by                                          
O-demethylation with BBr3 is known.19,24  
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Scheme 1.30 
In conclusion, the synthesis of (+)-O-methyl aphanorphine 14 (91% ee) was 
achieved from the readily available α-hydroxy acid derivative in 10 steps and 7.1% 
overall yield. A highly stereoselective intramolecular oxidative amidation was 
employed to construct the key pyrrolidine precursor to the benzazepine framework of 
the target. Notably, a N-formyl group serves as a N-methyl precursor in this synthesis. 
This avoided the more conventional approach in related aphanorphine syntheses that 
rely on N-deprotection, after the intramolecular Friedel-Crafts cyclization, followed 
by N-methylation. Since the N-deprotection step usually requires forcing conditions 
(detosylation14,24 using Red-Al in refluxing xylene) or debenzoylation20 (50% NaOH 
or KOH in ethanol, reflux, 24 h), the N-formylation approach provides a convenient 
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alternative that eliminates a late-stage step in the synthesis of other pyrrolidinone-
containing natural products. 
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1.4 Experimental section: 
General experimental methods 
 All commercially available reagent were used without purification. All 
reactions requiring anhydrous conditions were performed under an atmosphere of dry 
nitrogen using oven dried glassware. Dichloromethane and tetrahydrofuran were 
distilled from CaH2 and sodium/benzophenone respectively. Commercial precoated 
silica gel plates were used for TLC. Silica gel for column chromatography was 230-
400 mesh. All melting points are uncorrected. Optical rotations were measured at the 
sodium D line on a digital polarimeter at ambient temperature. 
(2R,5S,6R)-2-Allyl-2,4,5-trimethyl-6-phenylmorpholin-3-one (95): 
N
O
O
 
To a solution of 107 (0.50 g, 2.1 mmol) in CH2Cl2 (15 mL) was added 
allyltrimethylsilane (1.87 mL, 12.7 mmol) at −78 °C followed by BF3.OEt (1.57 mL, 
12.7 mmol). The solution was gradually warmed to ambient temperature and stirred 
for 20 h. The mixture was cooled to 0 °C and water (20 mL) was added. After stirring 
at ambient temperature for 5 min, the mixture was extracted with CH2Cl2 (3×30 mL). 
The combined extracts were dried (Na2SO4) and concentrated under reduced pressure. 
The residue was purified by flash chromatography on silica gel (EtOAc/ hexanes, 2/3) 
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to provide 95 (428 mg, 79%) as a colourless gum. The spectroscopic data was in 
agreement with the previously reported data. 
(R)-2-Hydroxy-2-methylpent-4-enoic acid (102): 
OH
OH
O
 
To a solution of the amide 94 (405 mg, 2.83 mmol) in THF-water (1:1, 14 mL) 
at ambient temperature was added iodine (1.69 g, 6.60 mmol) and the solution was 
stirred in the dark for 12 h. The solution was then extracted with ethyl acetate (3×20 
mL), and the combined extracts were washed with saturated aqueous sodium 
thiosulphate solution, dried (Na2SO4) and then concentrated under reduced pressure to 
provide a yellow gum (610 mg). This was dissolved in THF-water (1:1, 12 mL) and 
zinc (480 mg, 7.40 mmol) was added. The vigorously stirred mixture was heated at 50 
°C for 4 h, cooled to room temperature and the THF was removed under reduced 
pressure. The residue was cooled to 0 °C, aqueous HCl (4 M, 10 mL) was added and 
the mixture was stirred until all of the solids dissolved. The resulting acidic solution 
was extracted with EtOAc (3×50 mL) and the combined extracts were dried (Na2SO4) 
and concentrated under reduced pressure to provide a brown gum (982 mg). This was 
dissolved in EtOAc (10 mL) and the solution was extracted with saturated aqueous 
NaHCO3 (2×10 mL). The combined aqueous extracts were cooled to 0 °C, acidified 
with concentrated aqueous HCl and the resulting clear solution was extracted with 
EtOAc (3×30 mL). The combined extracts were dried (Na2SO4) and concentrated 
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under reduced pressure to provide a dark yellow gum (800 mg). Purification by flash 
chromatography on silica gel (EtOAc/hexanes, 1/1) provided the acid 102 (220 mg, 
59%) as a pale yellow gum.  
IR (neat): 3362, 2980, 1719, 1635, 1227, 1163, 919 cm-1. 
1H NMR (300 MHz, CDCl3): δ 5.85-5.74 (m, 1H, CH), 5.22 (s, 1H, CH=CH2), 5.18 
(d, 1H, J = 5.0, CH=CH2), 2.61 (dd, 1H, J = 7.1, 13.8, CH2CH), 2.44 (dd, 1H, J = 7.5, 
13.8, CH2CH), 1.50 (s, 3H, CH3). 
 13C NMR (75 MHz, CDCl3): δ 180.6 (C=O), 131.8 (CH=CH2), 120.0 (CH=CH2), 
74.4 (C-CO2H), 44.4 (CH2CH), 25.4 (CH3). 
MS (CI Neg.): m/z 128.9 (M-1). 
[]D25 = −11.1 (c 1, EtOH); lit.38 []D25 −5.2 (c 1, EtOH) for material with 42% ee). 
(R)-E-2-Hydroxy-5-(4-methoxyphenyl)-2-methylpent-4-enoic acid (103): 
HO
O
HO
OCH3  
To a solution of the acid 102 (300 mg, 2.30 mmol) in CH2Cl2 (4 mL) under 
nitrogen was added a solution of Grubbs’ II catalyst (390 mg, 0.046 mmol) in CH2Cl2 
(4 mL) followed by the addition of 4-vinylanisole (0.6 mL, 4.6 mmol). The solution 
was heated at reflux for 7 h, cooled to ambient temperature and the solvent was 
evaporated under reduced pressure to obtain a brown solid. This was dissolved in 
EtOAc (5 mL) and the solution was extracted with saturated aqueous NaHCO3 (2×5 
mL). The combined bicarbonate extracts were cooled and acidified to pH 2 with 
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concentrated aqueous HCl. The acidic solution was extracted with EtOAc (3×15 mL) 
and the combined organic layers were dried (Na2SO4) and concentrated under reduced 
pressure to provide 103 (380 mg, 70%) as a white solid. This was pure as determined 
by 1H NMR and was used without further purification. An analytical sample was 
obtained by flash chromatography on silica gel (EtOAC/hexanes, 1/1). 
Mp: 169-170 °C. 
IR (neat): 3434, 2932, 1720, 1509, 1274, 1247, 1202, 1150, 1103, 1027, 961 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.29 (d, 2H, J = 8.7, ArCH), 6.83 (d, 2H, J = 8.7, 
ArCH), 6.46 (d, 1H, J = 15.7, Ar-CH=CH), 6.09-5.98 (m, 1H, CH=CHCH2), 3.80 (s, 
3H, OCH3), 2.73 (dd, 1H, J = 7.2, 14.0, CH2-CH), 2.54 (dd, 1H, J = 7.8, 14.0, CH2-
CH), 1.52 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3): δ 180.7 (CO), 159.1 (ArC-OCH3), 134.2 (Ar-CH=CH), 
129.8 (ArCipso), 127.5 (ArC), 120.7 (Ar-CH=CH), 114.0 (ArC), 74.8 (CCH3), 55.3 
(Ar-OCH3), 43.6 (CH2), 25.3 (CH3). 
MS (CI Pos.): m/z 236 (M+); HRMS: (EI Pos., TOF) m/z 236.1046 (236.1049 calc. for 
C13H16O4 (M+)). 
[]D25 = −9.5 (c 0.5, CHCl3). 
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(R)-E-2-Hydroxy-N-methoxy-5-(4-methoxyphenyl)-2-methylpent-4-enamide 
(114): 
HO
O
H3COHN
OCH3  
To a solution of the acid 103 (400 mg, 2.54 mmol) in CH2Cl2 (15 mL)                                    
at 0 oC was added 4-methylmorpholine (0.29 mL, 2.6 mmol), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (536 mg, 2.80 mmol), 
methoxyamine hydrochloride (634 mg, 7.6 mmol) and solid Na2CO3 (694 mg, 7.6 
mmol). The resulting clear, brown solution was warmed to ambient temperature and 
stirred for 24 h. Aqueous HCl (0.5 M, 5 mL) was added and the layers were separated. 
The aqueous layer was extracted with CH2Cl2 (2×10 mL). The combined organic 
layers were washed with saturated aqueous NaHCO3 solution, dried (Na2SO4) and 
concentrated to provide the amide 114 (480 mg, 72%) as a brown gum. This was pure 
by 1H NMR and was used without further purification. An analytical sample was 
obtained by flash chromatography on silica gel (EtOAc/hexanes, 7/3). 
IR (neat): 3431, 2925, 1704, 1607, 1511, 1363, 1246, 1169 cm-1.  
1H NMR (300 MHz, CDCl3): δ 9.14 (bs, 1H, NH), 7.29 (d, 2H, J = 8.7, ArH), 6.85 (d, 
2H, J = 8.7, ArH), 6.48 (d, 1H, J = 15.8, Ar-CH=CH), 6.07-5.97 (m, 1H, CH=CHCH2), 
3.81 (s, 3H, N-OCH3), 3.77 (s, 3H, Ar-OCH3), 2.88 (dd, 1H, J = 7.2, 13.8, CH2CH), 
2.42 (dd, 1H, J = 8.4, 13.8, CH2CH), 2.25 (bs, 1H, OH), 1.49 (s, 3H, CH3).  
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13C NMR (75 MHz, CDCl3): δ 172.8 (CO), 159.2 (ArC-OCH3), 134.5 (ArCH=CH), 
129.0 (ArCipso), 127.4 (ArC), 121.1 (Ar-CH=CH), 114.0 (ArC), 75.5 (CCH3), 64.3 (N-
OCH3), 55.3 (Ar-OCH3), 43.7 (CH2), 26.0 (CH3).  
MS (CI Pos.): m/z 266 (M+H)+; HRMS (EI Pos., TOF): m/z 265.1315 (265.1314 calc. 
for C14H19NO4 (M+)).  
[]D25 = +10.9 (c 1, CHCl3). 
(3R,5S)-3-Hydroxy-5-(hydroxy(4-methoxyphenyl)methyl)-1-methoxy-3-
methylpyrrolidin-2-one (118): 
N
O
CH3O
CH3
HO
OCH3
OH
 
To a stirred solution of amide 114 (130 mg, 0.48 mmol) in CH2Cl2 (5 mL) at 
−10 °C (ice-salt bath) was added bis(trifluoroacetoxy)iodobenzene (252 mg, 0.58 
mmol). The solution was stirred at −10 oC for 90 min and aqueous NaOH (2.5 M, 1.0 
mL) was added. The mixture was stirred vigorously for 5 min at ambient temperature 
and the resulting biphasic mixture was separated. Aqueous layer was extracted by 
CH2Cl2 (2×10 mL). The combined organic layers were dried (Na2SO4) and 
concentrated under reduced pressure to provide a brown solid which was purified by 
flash chromatography on silica gel (EtOAc/hexanes, 4/1) to provide the pyrrolidone 
118 (88 mg, 68%) as a 5/1 mixture of diastereomers. 
IR (neat): 3367, 1691, 1511, 1244, 1174, 1024 cm-1.  
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1H NMR (500 MHz, CDCl3): Major diastereomer: δ 7.28 (d, 2H, J = 6.5 Hz, ArH), 
6.91 (d, 2H, J = 8.7 Hz, ArH), 5.14 (br d, 1H, J = 2.3, CH(OH)Ar), 4.05-4.03 (m, 1H, 
CHCH2), 3.91 (s,3H, N-OCH3), 3.81 (s, 3H, Ar-OCH3), 2.21 (d, 1H, J = 2.9, CHOH), 
2.10 (dd, 1H, J = 6.0, 13.7, CH2), 1.82 (dd, 1H, J = 8.1, 13.7, CH2), 1.44 (s, 3H, CH3). 
Visible peaks for the minor diastereomer: δ 7.95 (d, 2H, J = 9.0, ArH), 6.99 (d, 2H, 
J = 9.0, ArH), 4.20-4.16 (m, 1H, CHCH2), 3.90 (s, 3H, ArO-CH3), 3.81 (s, 3H, N-
OCH3), 2.18 (d, 1H, J = 12.3, CHOH), 2.02 (dd, 1H, J = 5.4, 13.4, CH2), 1.92 (dd, 1H, 
J = 8.0, 14.0, CH2).  
13C NMR (75MHz, CDCl3): Major diastereomer: δ 171.6 (CO), 159.3 (ArC-OCH3), 
131.2 (ArCipso), 127.0 (ArC), 113.9 (ArC), 71.6 (CCH3), 69.2 (CHOH), 62.1 (N-
OCH3), 59.6 (OCH3), 55.3 (CHN), 30.8 (CH2), 24.9 (CH3).  
Visible peaks for minor diastereomer: δ 130.8 (ArCipso), 128.1 (ArC), 61.7 (N-
OCH3), 34.3 (CH2).  
MS (CI Pos.): m/z 282 (M+H)+; HRMS (CI Pos., TOF): m/z 282.1342 (282.1341 
calculated for C14H20NO5 (M+H)+. 
(3R,5S)-5-(4-Methoxybenzyl)-3-hydroxy-1-methoxy-3-methylpyrrolidin-2-one 
(119): 
N
O
CH3O
CH3
HO
OCH3
 
To a mixture of pyrrolidone 118 (180 mg, 0.64 mmol) and triethylsilane (1.02 
mL, 6.40 mmol) at 0 oC was added trifluoroacetic acid (0.24 mL, 3.2 mmol) and the 
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mixture was stirred vigorously at ambient temperature for 7 h (the biphasic reaction 
mixture turned homogeneous after 7 h). Aqueous NaOH (1.0 M, 2.0 mL) was added 
and the mixture was extracted with EtOAc (3×10 mL). The combined organic layers 
were dried (Na2SO4) and concentrated to provide white solid (280 mg) which was 
purified using flash silica gel (EtOAc/hexanes, 8/2) to obtain 119 (130 mg, 94%) as a 
white solid. 
Mp:  95-97 °C.  
IR (neat): 3391, 1707, 1510, 1249, 1181, 1023 cm-1.  
1H NMR (500 MHz, CDCl3): δ 7.10 (d, 2H, J = 8.4, ArH), 6.85 (d, 2H, J = 8.4, ArH), 
4.11-4.09 (m, 1H, NCH), 3.87 (s, 3H, N-OCH3), 3.79 (s, 3H, Ar-OCH3), 3.05 (dd, 1H, 
J = 3.7, 13.7,  CH2Ar), 2.73 (dd, 1H, J = 8.0, 13.7, CH2Ar), 2.5 (bs, 1H, OH), 2.14 
(dd, 1H, J = 7.7, 13.7, CH2CH), 1.73 (dd, 1H, J = 5.9, 13.7, CH2CH), 1.18 (s, 3H, 
CH3).  
13C NMR (75 MHz, CDCl3): δ 170.9 (CO), 158.6 (ArC-OCH3), 130.6 (ArC), 127.7 
(ArCipso), 114.1 (ArC), 71.4 (CCH3), 62.0 (CHN), 55.3 (CH3O-N), 54.9 (Ar-OCH3), 
37.5 (ArCH2), 36.7 (CH2CH), 25.2 (CH3).  
MS (CI Pos.): m/z 266.1 (M+H)+; HRMS (CI Pos., TOF) m/z 265.1312 (265.1314 
calculated for C14H19NO4 (M+). 
 []D25 = −4.9 (c 1, CHCl3). 
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 (3R,5R)-5-(4-methoxybenzyl)-3-hydroxy-3-methylpyrrolidin-2-one (120): 
N
H
O
CH3
HO
OCH3
 
To a solution of amide 119 (60 mg, 0.22 mmol) in CH3CN:H2O (15/1, 6.0 mL) 
was added Mo(CO)6 (119 mg, 0.45 mmol) and the mixture was heated to reflux under 
nitrogen for 24 h. The reaction mixture turned yellow after 2 h and gradually turned 
green and then black. After 24 h the mixture was cooled to room temperature and 
concentrated. The black residue (180 mg) was purified by flash chromatography on 
silica gel (EtOAc/hexanes, 7/3 followed by EtOAc/MeOH, 9.5/0.5) to provide the 
pyrrolidone 120 (37 mg, 71%) as a white solid. 
Mp: 87- 89 °C.  
IR (neat): 3301, 2932, 1692, 1604, 1110, 612 cm-1.  
1H NMR (300 MHz, CD3OD): δ 7.12 (d, 2H, J = 8.6, ArH), 6.86 (d, 2H, J = 8.7, ArH), 
3.96-3.89 (m, 1H, CHNH), 3.76 (s, 3H, OCH3), 2.83 (dd, 1H, J = 5.7, 13.5 Hz, CH2Ar), 
2.65 (dd, 1H, J = 7.4, 13.6 Hz, CH2Ar), 2.13 (dd, 1H, J = 6.6, 13.3Hz, CH2CH),  1.79 
(dd, 1H, J = 6.5, 13.7 Hz, CH2CH),  1.24 (s, 3H, CH3).  
13C NMR (75 MHz, CD3OD): δ180.3 (CO), 160.1 (ArC-OCH3), 131.5 (ArC), 130.5 
(ArCipso), 115.0 (ArC), 75.3 (COH), 55.7 (OCH3), 53.5 (CHNH), 42.9 (CH2Ar), 42.0 
(CH2CH), 24.8 (CH3).  
MS (CI Pos.): m/z 235.27 (M+H)+; HRMS (EI Pos., TOF): m/z 235.1203 (235.1208 
calc. for C13H17NO3 (M+)).  
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[]D25 = −5.5 (c 1.0, acetone). 
(3R,5R)-5-(4-Methoxybenzyl)-3-methylpyrrolidin-3-ol (121):  
N
H
CH3
HO
OCH3
 
To a suspension of lithium aluminum hydride (129 mg, 3.40 mmol) in THF (1 
mL) at 0 °C was added a solution of the pyrrolidone 120 (100 mg, 0.42 mmol) in THF 
(3 mL) dropwise. The mixture was warmed to room temperature and then heated to 
reflux for 12 h. The mixture was cooled to 0 °C and water (0.1 mL), aqueous NaOH 
(2.5 M, 1.3 mL) and water (0.3 mL) were added sequentially with a 15 min stirring 
period between each addition and 20 min stirring after the last addition. The resulting 
mixture was filtered with suction and the white precipitate was washed with THF 
(2×10 mL). The combined filtrates were dried (Na2SO4) and concentrated.  The residue 
was dissolved in EtOAc (3 mL) and the solution was extracted with aqueous HCl          
(1 M, pH 5, 2×3 mL). The combined extracts were cooled (<5 oC) and basified to pH 
9 with NaOH pellets. The basic solution was extracted with EtOAc (3×10 mL) and the 
combined extracts were dried (Na2SO4) and concentrated to provide the pyrrolidine 
121 (74 mg 79%) as a yellow gum. This was pure by 1H NMR and was used without 
further purification. An analytical sample was obtained by flash chromatography on 
silica gel (CH2Cl2/MeOH, 9/1 containing 1% aq. ammonia). 
IR (neat): 3301, 2924, 1511, 1243, 1034 cm-1.  
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1H NMR (500 MHz, CDCl3): δ 7.13 (d, 2H, J = 8.6, ArH), 6.85 (d, 2H, J = 8.6, ArH), 
3.80 (s, 3H, OCH3), 3.69-3.64 (m, 1H, CHNH), 2.97-2.90 (AB system, 2H, J = 11.2, 
NHCH2), 2.75-2.67 (ABX system, 2H, J = 7.0, 13.6, ArCH2), 1.93 (dd, 1H, J = 6.3, 
13.2, NCHCH2), 1.48 (dd, 1H, J= 9.3, 13.2, NCHCH2), 1.40 (s, 3H, CH3).  
13C NMR (75 MHz, CDCl3): δ 158.1 (ArC-OCH3), 131.5 (ArCipso), 129.9 (ArC), 
113.9 (ArC), 79.0 (CCH3), 59.7 (NHCH2), 59.4 (NHCH), 55.3 (Ar-OCH3), 47.3 
(CH2), 41.5 (ArCH2), 26.4 (CH3). 
MS (CI Pos.): m/z 222.1 (M+H)+; HRMS (CI Pos., TOF): m/z 222.1489 (222.1494 
calc. for C13H20NO2(M+1)+).  
[]D25 = −70 (c 0.5, CHCl3). 
(−)-(2R,4R)-5-(4-Methoxybenzyl)-3-methyl-1-tosylpyrrolidin-3-ol (122): 
N
CH3
HO
OCH3
Ts  
To a stirred solution of p-toluenesulfonyl chloride (19.40 mg, 0.10 mmol) in 
THF (0.5 mL) was added freshly distilled triethylamine (19.0 μL, 0.14 mmol) at 0 °C, 
followed by a solution of the amine 121 (15 mg, 0.07 mmol) in THF (1.0 mL). The 
mixture was stirred for 8 h at ambient temperature and then saturated, aqueous 
NaHCO3 (2 mL) was added. The mixture was extracted with CH2Cl2 (3 x 10 mL) and 
the combined extracts were dried (Na2SO4) and concentrated. The residue was purified 
by flash chromatography on silica gel (EtOAc/hexanes, 1/1) to provide 122 (19 mg, 
75%) as an off-white foam. 
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IR: 3508, 2929, 1511, 1331, 1245, 1151, 1088, 1033 cm-1.  
1H NMR (300 MHz, CDCl3): δ 7.81 (d, 2H, J = 8.1, ArH), 7.34 (d, 2H, J = 8.1, ArH), 
7.15 (d, 2H, J = 8.6, ArH), 6.83 (d, 2H, J = 8.6, ArH), 4.02-3.94 (m, 1H, CHNTs), 
3.78 (s, 3H, OCH3), 3.39 (dd, 1H, J = 2.3, 12.4, CH2NTs), 3.31 (dd, 1H, J = 3.5, 13.5 
Hz, CH2Ar), 3.17 (d, 1H, J = 12.4, CH2NTs), 2.85 (dd, 1H, J = 8.8, 13.5, CH2Ar), 2.42 
(s, 3H, ArCH3), 1.80-1.75 (ddd, 1H, J = 2.3, 6.9, 13.4, CH2CH), 1.60 (dd, 1H, J = 9.7, 
13.3 Hz, CH2CH), 1.19 (s, 3H, CH3).  
13C NMR (75 MHz, CDCl3): δ 158.3 (ArC-OCH3), 143.6 (ArC-CH3), 135.0 (ArCTs), 
130.6 (ArC), 129.72 (ArCipso), 129.65 (ArC), 127.8 (ArC), 113.8 (ArC), 76.0 (CCH3), 
61.6 (CH2N), 61.1 (OCH3), 55.2 (CHNTs), 45.6 (CH2), 41.0 (ArCH2), 24.2 (CH3), 
21.6 (ArCH3).  
MS (CI Pos.): m/z 376.1 (M+H)+; HRMS (CI Pos., TOF): m/z 376.1589 (376.1583 
calc. for C20H26NO4S (M+H)+).  
[]D25 = −76.8 (c 0.5, CHCl3). 
(−)-(1R,4S)-8-Methoxy-1-methyl-3-tosyl-2,3,4,5-tetrahydro-1H-1,4-
methanobenzo[d]azepine (19): 
 
To a suspension of AlCl3 (44 mg, 0.34 mmol) in CH2Cl2 at 0 °C was added a 
solution of 121 (12 mg, 0.03 mmol). The mixture was warmed to ambient temperature 
and stirred for 9 h. The resulting brown solution was poured into saturated aqueous 
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NaHCO3 (3 mL) and the mixture was extracted with CH2Cl2 (3×10 mL). The 
combined organic layers were dried (Na2SO4) and concentrated to provide a yellow 
solid which was purified by flash chromatography on silica gel (EtOAc/hexanes, 2/3) 
to provide 19 (8 mg, 72%) as a pale yellow solid. 
Mp: 136-138 oC (lit.2 Mp: 136-138 °C).  
IR: 2924, 1336, 1291, 1236, 1154, 1093, 1043, 809 cm-1.  
1H NMR (500 MHz, CDCl3): δ 7.69 (d, 2H, J = 8.3, ArH), 7.28 (d, 2H, J= 8.0, ArH), 
6.97 (d, 2H, J = 8.3, ArH), 6.77 (d, 1H, J = 2.6, ArH), 6.71 (dd, 1H, J = 2.7, 8.3, ArH), 
4.38 (m, 1H, CH-NTs), 3.77(s, 3H, OCH3), 3.39 (dd, 1H, J = 1.3, 8.6, ArCH2), 3.11 
(d, 1H, J = 16.5, CH2-NTs), 3.02 (d, 1H, J = 8.6, CH2-NTs), 2.92 (dd, 1H, J = 2.9, 
16.5, ArCH2), 2.42 (s, 3H, ArCH3), 1.79 (d, 1H, J = 11.2, CH2CH), 1.47 (dd, 1H, J = 
1.3, 6.2, 11.2, CH2CH), 1.40 (s, 3H, CH3).  
13C NMR (75 MHz, CDCl3): δ 158.0 (ArC-OCH3), 145.0 (ArCipso), 143.1 (ArCCH3), 
135.8 (ArCipso), 130.4 (ArC), 129.6 (ArC), 127.1 (ArC), 125.3 (ArCipso), 111.7 (ArC), 
110.1 (ArC), 63.0 (OCH3), 57.8 (CH2N), 55.3 (CHN), 42.4 (CH3-C-CH2), 41.7 (CH3-
C-CH2), 38.4 (CH2Ar), 21.6 (ArCH3), 20.8 (CH3).  
MS: (CI Pos.): m/z 358.1 (M+H)+; HRMS (EI Pos., TOF): m/z 357.1394 (357.1399 
calc. for C20H23NO3S (M+).  
[]D25 = −18.9 (c 0.9, CHCl3; lit.12 []D25 −16.9 (c 0.89, CHCl3).  
HPLC: Chiralpak   AD-H, hexanes/2-propanol 72/25, 254 nm, t1 = 7.4 min (minor), t2 
= 8.9 min (major), ee: 91%; [lit.24 t1 = 8.04 min, t2 = 9.80 min]. 
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(−)-(1R,4S)-8-Methoxy-1-methyl-4,5-dihydro-1H-1,4-methanobenzo[d]azepine-
3(2H)-carbaldehyde (123): 
 
To a solution of 121 (30 mg, 0.13 mmol) in CH2Cl2 (2.5 mL) was added acetic 
formic anhydride (14 µL, 0.15 mmol). The mixture was stirred at room temperature 
for 4 h and then concentrated under reduced pressure to provide the N-formyl 
derivative 29 mg as a yellow gum. This was dissolved in CH2Cl2 (0.5 mL) and the 
solution was added dropwise to a cold (0 oC), stirred suspension of AlCl3 (162 mg, 
1.21 mmol) in CH2Cl2 (0.5 mL). The mixture was then stirred at ambient temperature 
for 24h, cooled to 0 °C and saturated aqueous NaHCO3 (2 mL) was added. The 
biphasic solution was transferred to a separatory funnel and extracted with CH2Cl2 
(3×5 mL). The combined extracts were dried (Na2SO4) and concentrated to provide a 
pale yellow gum. Purification by flash chromatography on silica gel (CH2Cl2/MeOH 
9.5/0.5) provided 123 (23 mg, 88%) as a colourless gum. 
IR: 2955, 1657, 1612, 1417, 1233, 1036 cm-1.  
1H NMR (300 MHz, CDCl3): Major rotamer : δ 8.34 (s, 1H, HCO), 7.01 (d, 1H, J = 
8.4, ArH), 6.82 (d, 1H, J = 2.6, ArH), 6.73 (dd, 2H, J = 2.6, 8.2, ArH), 4.42-4.41 (m, 
1H, CH), 3.78 (s, 3H, OCH3), 3.53 (d, 1H, J = 11.2, CH2Ar ), 3.24 (d, 2H, J = 12.1, 
CH2N), 2.93 (d, 2H, J = 16.6, CH2Ar), 2.02 (dd, 1H, J =1.4, 5.5, CH2), 1.97 (dd, 1H, 
J = 1.3, 5.0, CH2 ), 1.55 (s, 3H, CH3). 
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Minor rotamer: δ 8.10 (s, 1H, HCO), 7.02 (d, 1H, J = 8.4, ArH), 6.84 (d, 1H, J = 2.6, 
ArH), 4.65 (m, 1H, CHN), 3.79 (s, 3H, OCH3), 3.48 (d, 1H, J = 9.2, CH2N), 3.40 (d, 
1H, J = 9.2,CH2N), 3.13 (dd, 1H, J = 2.8, 16.5, CH2Ar), 1.55 (s, 3H, CH3).  
13C NMR (75 MHz, CDCl3): Major rotamer: δ 160.3 (CO), 157.9 (ArC-OCH3), 
145.4 (ArC-CCH3), 130.2 (ArC), 123.8 (ArCipso), 111.6 (ArC), 109.7 (ArC), 58.8 
(CH2N), 55.1 (CH3O), 52.5 (CHN), 41.4 (CH2CH), 38.9 (CCH3), 34.9 (CH2Ar), 20.7 
(CH3).  
Minor rotamer: δ 160.4 (CO), 157.8 (ArC-OCH3), 144.6 (ArC-CCH3), 130.4 (ArC), 
125.2 (ArCipso), 111.5 (ArC), 109.8 (ArC), 63.7 (CHN), 60.6 (CH2N), 54.7 (CH3O), 
40.4 (CCH3), 20.5 (CH3).  
MS: (CI Pos.): m/z 232.1 (M+H)+; HRMS (EI Pos., TOF): m/z 231.1264 (231.1259 
calc. for C14H17NO2 (M+).  
[]D25 = −23.2 (c 1, CHCl3). 
(+)-8-O-Methylaphanorphine (14): 
 
 A solution of the formamide 123 (10 mg, 0.04 mmol) in ether (0.5 mL) was 
added to a stirred suspension of lithium aluminium hydride (5 mg, 0.12 mmol) in 
diethylether (0.5 mL) at 0 °C and the resulting mixture was stirred at ambient 
temperature for 7 h. The mixture was then cooled to 0 °C and treated sequentially with 
water (3µL), aqueous NaOH (2.5 M, 50 L), and water (9 µL) with 5 min of stirring 
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after each addition. The resulting mixture was filtered with suction and the solid 
residue was washed several times with ether. The combined filtrates were dried 
(Na2SO4) and concentrated to provide (+)-8-O-methylaphanorphine 14 (7 mg, 74%) 
as a yellow liquid. 
IR: 2923, 1611, 1577, 1290, 1040, 804 cm-1.  
1H NMR (500 MHz, CDCl3): δ 7.01 (d, 1H, J = 8.3, ArH), 6.78 (d, 1H, J = 2.6, ArH), 
6.67 (dd, 1H, J = 2.6, 8.3, ArH), 3.77 (s, 3H, OCH3), 3.40 (m, 1H, NCH), 3.02 (d, 1H, 
J =16.7, CH2), 2.85 (dd, 1H, J = 3.1, 7.9, ArCH2), 2.83 (d, 1H, J = 9.0, ArCH2), 2.74 
(d, 1H, J = 9.0, NCH2), 2.47 (s, 3H, OCH3), 2.02 (dd, 1H, J = 5.2, 10.8, CH2), 1.85 (d, 
1H, J = 10.9, CH2) 1.48 (s, 3H, CH3).  
13C NMR (75 MHz, CDCl3): δ 157.4 (ArC-OCH3), 147.9 (ArC-CCH3), 130.0 (ArC), 
125.9 (ArCipso), 110.7 (ArC), 109.2 (ArC), 71.2 (CH-NCH3), 61.1 (CH2-NCH3), 55.0 
(OCH3), 43.0 (CH2), 41.3 (NCH3), 35.5 (CCH3), 29.5 (CH2), 21.3 (CH3).  
MS (CI Pos): m/z 218.1(M+H)+; HRMS (CI Pos., TOF): m/z 217.1467 (217.1467 calc. 
for C14H19NO (M+).  
[]D25 = +21.3 (c 0.4, (CHCl3), lit.3 []D23= +9.39 (c 0.30, CHCl3). 
(3R)-3-Hydroxy-5-(iodomethyl)-1,3-dimethylpyrrolidin-2-one (109): 
N
H3C
HO
CH3
IO
 
To a solution of the amide 94 (0.27 g, 1.9 mmol) in CH2Cl2 (6 mL) at 0 oC, 
was added freshly distilled triethylamine (0.58 mL, 4.2 mmol) and freshly distilled 
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trimethylsilyltriflate (0.78 mL, 4.2 mmol). The resulting brown solution was warmed 
to room temperature and stirred for 45 min. The mixture was cooled to 0 °C and a 
solution of iodine (1.07g, 4.21 mmol) in CH2Cl2 (19 mL) was added. The mixture was 
stirred at room temperature for 20 h and a saturated solution of NaHCO3 (25 mL) was 
added. The mixture was stirred for 30 min and the phases were separated. The aqueous 
phase was extracted with CH2Cl2 (2×30 mL), the combined organic phases were 
washed with saturated, aqueous sodium thiosulfate (15 mL), dried (Na2SO4) and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/hexanes, 8/2) to provide the iodolactam 109 
(0.43g, 83.8%) as 1.6:1 mixture of diasteroemers. 
IR (neat): 3316, 2361, 1682, 1254 cm-1.  
1H NMR (500 MHz, CDCl3): Major diastereomer: δ 3.48-3.35 (m, 2H, CH-NCH3, 
CH2I), 3.33-3.27 (m, 1H, CH2I), 2.84 (s, 3H, N-CH3), 2.34 (dd, 1H, J = 7.7, 14.0, CH3-
C-CH2), 1.81 (dd, 1H, J = 5.5, 14.0, CH3-C-CH2), 1.51 (s, 3H, CH3).  
Minor diastereomer: δ 3.48-3.35 (m, 2H, CH-NCH3, CH2I), 3.33-3.27 (m, 1H, CH2I), 
2.87 (s, 3H, N-CH3), 2.27 (dd, 1H, J = 7.0, 13.3, CH3-C-CH2), 2.00 (dd, 1H, J = 6.1, 
13.3, CH3-C-CH2), 1.40 (s, 3H, CH3).  
13C NMR (75 MHz, CDCl3): Major diastereomer: δ 177.1 (CO), 73.8 (C(OH)CH3), 
56.6 (CHNCH3), 40.9 (CH2), 28.0 (N-CH3), 25.2 (CH3), 8.6 (CH2I).  
Minor diastereomer: δ 175.1 (CO), 73.9 (C(OH)CH3), 56.1 (CHNCH3), 40.2 (CH2), 
27.8 (N-CH3), 20.7 (CH3), 10.6 (CH2I).  
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MS (CI Pos.): m/z 270.0 (M+H)+; HRMS (EI Pos., TOF): m/z 268.9915 (268.9913 
calculated for C7H12INO2 (M+)). 
(E)-2-hydroxy-5-(4-methoxyphenyl)-N, 2-dimethylpent-4-enamide (93): 
N
H
O
OH
O  
To a stirred solution of acid 103 (0.12 g, 0.50 mmol) in THF at 0 °C, was added 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (0.145 g, 0.760 
mmol), ethyl cyanoglyoxylate-2-oxime (0.10 g, 0.76 mmol), methylamine solution 
(2.0 M in THF, 0.50 mL,1.01 mmol) and the solution was stirred for a further 24 h. 
Hydrochloride solution (1 M, 10 mL) was added, stirred for 5 min and warmed to room 
temperature. THF was removed under reduced pressure, the residue extracted using 
CH2Cl2 (2×15 mL) and the combined organic layers were washed with a saturated 
solution of NaHCO3 (10 mL), dried (Na2SO4) and concentrated to obtain crude amide 
as a brown gum. Flash silica gel chromatography (EtOAc/hexane 7/3) gave pure amide 
93 as a yellow gum (55 mg, 43.6%). 
IR: 3380, 2928, 1647, 1510, 1245, 1028, 730 cm-1.  
1H NMR (500 MHz, CDCl3): δ 7.28 (d, 2H, J = 8.8, ArH), 6.83 (d, 2H, J = 8.8, ArH), 
6.44 (d, 2H, J = 15.8, ArCH), 6.01 (ddd, 1H, J = 6.8, 8.4, 15.4, CHCH2), 3.79 (s, 3H, 
OCH3), 2.83 (ddd, 1H, J = 1.3, 6.9, 8.5, CH2CH), 2.81 (d, 3H, J = 4.9, NCH3), 2.44 
(ddd, 1H, J = 1.0, 8.5, 9.5, CH2CH), 1.45 (s, 3H, CH3).  
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13C NMR (75 MHz, CDCl3): δ 176.2 (CO), 159.2 (ArC-OCH3), 134.4 (CHAr), 129.7 
(ArCipso), 127.4 (ArC), 121.6 (CHCH2), 114.0 (ArC), 75.5 (CCH3), 55.3 (O-CH3), 
43.7(CH2), 26.1 (N-CH3), 26.0 (CH3).  
MS (CI Pos): m/z 250.0 (M+H)+; HRMS (CI Pos., TOF): m/z 250.1445 (250.1443 
calculated for C14H20NO3 (M+H)+). 
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1.6 Selected 1H and 13C NMR spectra 
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Studies on the synthesis of Clauslactone S 
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2.1 Introduction to Clauslactone S 
Clauslactone S (1) is a coumarin containing a C10 terpenoid side-chain.1 It has been 
extracted from the leaves and stem of Clausena excavata (commonly known as Rutaceae). 
Extracts of the plant stems and leaves have been used in Chinese folk medicine in the 
treatment of dysentery, enteritis and urethra infection.2 Chemical constituents of the plant 
include carbazole alkaloids,3 coumarins4 and tetranortriterpenoids.5 Ye and co-workers 
isolated a total of fourteen known coumarins and eleven carbazole alkaloids along with the 
three new coumarins bearing a C10 terpenoid side-chain, which were named as 
Clauslactone S (1), Clauslactone R (2) and Clauslactone T (3, Figure 2.1).1 Other 
coumarins featuring a C10 terpenoid side chain are also known and these have shown 
inhibitory effects on the Epstein-Barr virus4a and in the inhibition of two-stage mouse-skin 
carcinogenesis.4a 
 
Figure 2.1. Structures of clauslactone S, R and T. 
 
74 
 
2.2  Present work: 
2.2.1  Studies on the synthesis of clauslactone S 
The synthesis of clauslactone S has not previously been reported. The configuration 
of the C-8’ quaternary center in the lactone was reported to be R, based on the NOE 
correlations of H-6’/Ha-7’ and CH3-10’/Hb-7’. Similarly, the configurations at C-2’, C-3’ 
and C-6’ were deduced as R, R, and S, respectively, based on a ROESY experiment. The 
NOE and ROESY experiment results were confirmed by X-ray crystallography (Figure 
2.2). 
 
Figure 2.2 Structural details of clauslactone S. 
 Our interest in the synthesis of clauslactone S derives from the α-hydroxy acid 
motif in the lactone portion of the molecule, and also that its synthesis has not previously 
been reported, which makes it even more interesting as a synthetic target. 
Retrosynthetically, the lactone ring in clauslactone S was envisioned to derive from 
the α-hydroxy amide 6 as a starting material. The synthetic strategy involves a 
halolactonization reaction of the intermediate 4 to obtain the lactone in clauslactone S. The 
intermediate 4 was the expected product of a cross-metathesis reaction of an 
enantiomerically-enriched α-hydroxy amide 6 with an epoxy alkene 5. The amide 6 can be 
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obtained by the asymmetric allylation of a chiral pyruvic acid derivative obtained by 
amidation with (1R,2S)-ephedrine (9) (Scheme 2.1).  
 
Scheme 2.1 Retrosynthetic analysis of clauslactone S. 
The initial approach was aimed at the synthesis of the intermediate 4 which can be 
obtained from the coumarin derivative 5 and the amide 6. The synthesis of amide 6 is 
explained in Chapter 1 (Scheme 1.25, p 26) of this thesis. The synthesis of 5 started with 
the synthesis of epoxy alkene 11. Treatment of triethyl phosphonoacetate 14 with excess 
NaH followed by addition of pyruvaldehyde dimethylacetal 15 furnished 16 as a mixture 
of isomers (E/E = 1:2, Scheme 2.2). Stirring the acetal-ester 16 in CH2Cl2/3 M aqueous 
HCl afforded E-17 as a single isomer.6 Wittig reaction of 17 with the anion generated from 
methyltriphenylphosphonium bromide, using n-BuLi, provided the diene ester 18. The 
ester 18 was reduced with LiAlH4 to obtain the alcohol 13 (Scheme 2.2).7 
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Scheme 2.2 
The low yield of the Wittig reaction (conversion of 17 to 18) is probably due to the volatile 
nature of 18 which results in evaporative loss during its isolation and purification. 
 Allylic alcohol 13 was subjected to the Sharpless asymmetric epoxidation with         
t-butyl hydroperoxide (TBHP) in the presence of Ti(O-iPr)4 and (−)-diisopropyl tartrate to 
provide the epoxy alcohol 12 (65% yield of the crude product, Scheme 2.3). Attempted 
purification of 12 by chromatography on silica gel resulted in extensive decomposition and 
provided only a 10% yield of 9. Therefore, it was decided to employ 12 without purification 
in further reactions. Attempted conversion of 12 to the bromoepoxide 11 by treatment with 
PPh3, CBr4, and Et3N again led to extensive decomposition and only a trace of the desired 
product 11 was observed in the 1H NMR spectrum. This prompted a modification of the 
planned synthetic strategy.  
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Scheme 2.3 
 The modified synthetic sequence involved the lactonization and the epoxidation 
steps as late-stage synthetic transformations to obtain clauslactone S from 19 (Scheme 2.4). 
The intermediate 19 could in turn be obtained from the cross-metathesis reaction of the 
enantiomerically-enriched α-hydroxy amide 6 and coumarin derivative 20. O-Alkylation 
of coumarin 10 with bromodiene 21 could provide 20. The bromodiene can be obtained 
from the alcohol 13 which could be prepared from pyruvaldehyde dimethylacetal 15 as 
shown in Scheme 2.2 
Scheme 2.4 Modified retrosynthesis for clauslactone S. 
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 The synthesis of coumaryl ether 20 started with the selective methylation of 
pyrogallol 22. Treatment of 22 with Li2CO3 and MeI provided 23 in 78% yield.8 A variety 
of conditions were screened for the conversion of 23 to coumarin 10. Details of these 
experiments are provided in Table 1. The best result was obtained when 23 was treated 
with malic acid 24 and H2SO4 for 30 min at 95-115 °C.9 Alcohol 13 was converted to the 
corresponding bromide 21 by treatment with PBr3. O-Alkylation of 10 with the bromodiene 
21 provided coumaryl ether 20 in 75% yield (Scheme 2.5). This reaction did not go to 
completion and the yield reported is based on the amount of recovered starting material 10. 
 
Scheme 2.5  
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Table 2.1 Optimization of reaction conditions for the synthesis of 10 
 
Entry Acid Temperature (°C) Time Result Yield (%) 
1 HClO4 95 4 h decomposition - 
  20-25 5 h 23 - 
2 H2SO4  80 1.5 h 10 7a 
  rt- 80 3 h complex mixture - 
  80 2 h 10 14 
  120 20 min 10 3 
  95-115 30 min 10 55 
  120b 30+30 sec decomposition - 
  145b 15 sec 10 trace 
  50b 30 sec 10 trace 
3 p-TsOH 20-25 20 min complex mixture - 
a: 75% H2SO4 was used for the reaction. b: microwave heating in a sealed reaction vessel. 
Next, the cross-metathesis reaction of amide 6 and its corresponding acid 25 was 
attempted with dienes 18, 13 and 20 using the Grubbs II catalyst. The results of these 
reactions are summarized in Scheme 2.6. The ester 18 is a better cross-metathesis substrate 
than alcohol 10 and the cross metathesis of 25 and 6 with 18 provided 26 and 27, 
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respectively, in low yield. The best result was obtained with 6 and coumarin derivative 20 
which provided the cross-metathesis product 19 in 41% yield.  
Scheme 2.6 Screening of the cross-metathesis reaction substrates.  
With the amidodiene 19 in hand, its iodolactonization reaction was attempted. 
Unfortunately, treatment of 19 with iodine in CH2Cl2  led to a complex mixture of products 
which did not contain any of the desired lactone 31. This result was unanticipated since the 
the iodolactonization of 4,6-dienoic acids that are structurally related to 19 is known, and 
the lactonization proceeds with iodination at C-510 (Scheme 2.7). At this stage, further 
studies with 19 were discontinued due to the time constraints of the author.  
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Scheme 2.7 
2.2.2 Future studies towards the synthesis of clauslactone S 
 Provided that the halolactonization of the dienamide 19 is successful, and 31 is 
obtained, the dehalogenation of 31 may provide 32. Epoxidation of 32 may furnish the 
basic structure of clauslactone S (2, Scheme 2.8). Determination of the stereochemistry of 
the halolactonization and epoxidation steps will be crucial and optimization of these steps 
will depend on the stereochemical outcomes. 
Scheme 2.8 
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 In conclusion, the synthesis of a potential intermediate to clauslactone S was 
accomplished using the α-hydroxy amide 6 as a key starting material. The synthesis was 
designed as the assembly of three components 6, 10 and 13 which can be obtained from 
readily available starting materials. The Wittig reaction of 17 and the cross metathesis 
reaction that provides 19 needs to be optimized for better yields. 
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2.3 Experimental section: 
General experimental methods 
 All commercially available reagent were used without purification. All reactions 
requiring anhydrous conditions were performed under an atmosphere of dry nitrogen using 
oven dried glassware. Dichloromethane and tetrahydrofuran were distilled from CaH2 and 
sodium/benzophenone respectively. Commercial precoated silica gel plates were used for 
TLC. Silica gel for column chromatography was 230-400 mesh. All melting points are 
uncorrected.  
(E)-Ethyl 3-methyl-4-oxobut-2-enoate (17)6:  
 
To an oven-dried flask equipped with a N2 inlet was added 60% NaH in mineral oil 
(0.71 g, 17.7 mmol). The mineral oil was removed by washing with hexane. Dry THF (20 
mL) was added and the suspension was cooled (0 °C) with stirring. Triethyl 
phosphonoacetate 14 (3.35 mL, 16.9 mmol) was then added and the mixture was stirred 
for 1 h. Pyruvaldehyde dimethylacetal 15 (2.05 g, 16.9 mmol) was added and stirring was 
continued for 24 h at room temperature. The resulting solution was diluted with H2O and 
extracted with EtOAc (2×40 mL). The combined organic extracts were washed with brine, 
dried (Na2SO4), and concentrated to provide 16 (2.76 g, 91%) as a pale yellow liquid.  
To a solution of 16 in CH2Cl2 (10 mL) was added aqueous HCl (3 M, 10 mL) and 
the mixture was stirred at room temperature for 15 h. The organic layer was separated and 
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washed with saturated aqueous NaHCO3, brine, dried (Na2SO4) and then concentrated on 
a rotary evaporator at 15 °C to provide a yellow oil. Purification by flash chromatography 
on silica gel (CH2Cl2) provided aldehyde 17 (2.12 g, 89%) as a colourless liquid. 
IR (neat): 2987, 1699 (br), 1645, 1280, 1214, 1163, 1122, 1036 cm-1.  
1H NMR (300 MHz, CDCl3): δ 9.55 (s, 1H, CHO), 6.50 (q, 1H, J = 1.5, CHCO), 4.28 (q, 
1H, J = 7.1, CH2CH3), 2.16 (d, 2H, J = 1.5, CH3C=CH), 1.35 (t, 3H, J = 7.1, CH2CH3).  
13C NMR (75 MHz, CDCl3): δ 194.5 (CHO), 165.5 (CO2CH2CH3), 150.3 (C-CHO), 135.2 
(CH-CO2CH2CH3), 61.0 (CH2CH3), 14.4 (CH3), 10.8 (CH3).  
MS (CI Pos): m/z 143.1 (M+H)+. 
(E)-Ethyl 3-methylpenta-2,4-dienoate (18)7:  
 
A solution of n-butyllithium (1.66 M, 2.10 mL, 3.49 mmoL) was added dropwise 
to a suspension of methyltriphenylphosphium bromide (1.22 g, 3.40 mmol) in THF (10 
mL) at −78 °C. The mixture was brought to 0 °C and stirred for 1 h After cooling to −78 
°C, a solution of 17(0.50 g, 3.20 mmol) in THF (3 mL) was added slowly. The mixture was 
stirred for 24 h at room temperature, water was added and the mixture was extracted with 
Et2O (3×20 mL). The combined organic phases were dried (MgSO4) and the solvent was 
removed by distillation. The residue was purified by flash chromatography (pentane/Et2O, 
40/1). Fractions containing the product were pooled and the solvent was removed by 
distillation (45 °C) at atmospheric pressure to provide 18 (0.21 g, 44%) as a yellow liquid. 
IR (neat): 2948, 1711, 1603, 1232, 1156, 1074, 1032 cm-1.  
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1H NMR (300 MHz, CDCl3): δ 6.40 (apparent dd, 1H, J = 17.4, 10.7, CH=CH2), 5.79 (br 
s, 1H, CHCO), 5.61 (apparent d, 1H, J = 17.4, CH2=CH), 5.38 (apparent d, 1H, J = 10.7, 
CH2=CH), 4.18 (q, 2H, J = 7.1, CH2CH3), 2.27 (d, 3H, J = 1.4, CH3), 1.29 (t, 3H, J = 7.1, 
CH2CH3).  
13C NMR (75 MHz, CDCl3): δ 167.0 (CO2CH2CH3), 152.0 (H3C-C=CH), 140.2 
(CH=CH2), 120.0 (HC-C=O), 119.4 (CH2=CH), 59.8 (CH2CH3), 14.3 (CH3), 13.1 (CH3); 
MS (CI Pos): m/z 141.1 (M+H)+. 
(E)-3-Methylpenta-2,4-dien-1-ol (13)7  
 
A solution of 18 (1.10 g, 7.14 mmol) in anhydrous Et2O (4 mL) was added to a 
suspension of LiAlH4 (0.54 g, 14.2 mmol) in anhydrous Et2O (10 mL) at 0 °C under a N2 
atmosphere. The mixture was stirred at 0 °C for 30 min and cold H2O was added. The 
residue formed was dissolved by addition of a 10% aqueous solution of H2SO4. The 
resulting biphasic mixture was separated and the aqueous phase was extracted with Et2O 
(2×10 mL). The combined extracts were dried (MgSO4) and concentrated to provide 13 
(0.58 g, 83%) as a yellow liquid. 
IR (neat): 3379, 2926, 2859, 1609, 1439, 997, 897 cm-1.  
1H NMR (300 MHz, CDCl3): δ 6.39 (apparent dd, 1H, J = 17.4, 10.7, CH=CH2), 5.68 (br 
t, 1H, J =   CHCH2OH), 5.25 (apparent d, 1H, J = , CH=CH2), 5.07 (br d, 1H, J = 5.7, 
CH=CH2), 4.30 (t, 2H, J = 5.4, CH2CH), 2.17 (s, 1H, OH), 1.79 (m, 3H, CH3).  
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13C NMR (75 MHz, CDCl3): δ 140.7 (CH2=CH), 136.5 (C-CH3), 130.4 (CH-CH2OH), 
113.2 (CH2=CH), 59.4 (CH2OH), 11.9 (CH3). 
2-Methoxybenzene-1,3-diol (21)8: 
 
Lithium carbonate (0.73 g, 9.9 mmol) was added to a solution of pyrogallol (22) 
(0.50 g, 3.9 mmol) in N,N-dimethylformamide (15 mL) at room temperature. After 5 min, 
methyl iodide (0.61 mL, 9.9 mmol) was added and the resulting solution was heated at 50 
°C for 48 h. It was then cooled to room temperature, water (50 mL) was added and the 
solution was extracted with EtOAc (3×60 mL). The combined extracts were dried 
(Na2SO4), filtered, and concentrated. The residue was purified by flash silica 
chromatography on silica gel (EtOAc/hexanes, 1/1) to provide 23 (0.43 g, 78%) as white 
amorphous solid. 
Mp: 82-84 °C (lit.11 Mp 84.5-85 °C).  
IR (neat): 3361 (br), 3323 (br), 2940, 1605, 1485, 1357, 1204, 1156, 1064, 1018, 982        
cm-1.  
1H NMR (300 MHz, CDCl3): δ 6.87 (t, 1H, J = 8.1, ArH), 6.51 (d, 2H  J = 8.1, ArH), 5.33 
(s, 2H, OH), 3.88 (s, 3H, OCH3).  
13C NMR (75 MHz, CDCl3): δ 149.0 (2 × ArC-OH), 134.7 (ArC-OCH3), 124.8 (ArC), 
108.2 (2 × ArC), 61.2 (OCH3).  
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MS (CI Pos.): m/z 141.1 (M+H)+; HRMS (EI Pos., TOF): m/z 140.0472 (140.0473 calcd. 
for C7H8O3 (M+)). 
7-Hydroxy-8-methoxy-2H-chromen-2-one (10): 
 
A mixture of 20 (0.20 g, 1.4 mmol), malic acid (24) (0.19 g, 1.4 mmol) and conc. 
sulphuric acid (0.5 mL) was heated for 10 min at 95 °C and then in an oil bath at 100-115 
°C for 15 min by which time evolution of carbon monoxide had ceased. A mixture of ice 
and water (10 mL) was added and the brown solid which precipitated was isolated by 
filtration. The gummy residue which separated at the bottom of the flask was dissolved in 
hot methanol (3 mL) and the solution was concentrated to obtain a black solid. The two 
solids were mixed and purified by flash chromatography on silica gel (EtOAc/hexanes, 
1/4) to provide the coumarin 10 (0.14 g, 55%) as a pale yellow solid. 
Mp: 185-187 °C (lit.12 Mp 186.5 °C).  
IR (neat): 3328, 2934, 1695, 1602, 1570, 1504, 1444, 1331, 1200, 1156, 1126, 1066, 1022 
cm-1.  
1H NMR (300 MHz, CDCl3): δ 7.62 (d, 1H,  J = 9.5, CH=CH-C=O), 7.11 (d, 1H, J = 8.5, 
ArH), 6.90 (d, 1H, J = 8.5, ArH), 6.24 (d, 1H, J = 9.5, CH-C=O), 6.18 (s, 1H, OH), 4.13 
(s, 3H, OCH3).  
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13C NMR (75 MHz, CDCl3): δ 160.5 (CO2), 152.1 (ArC-OH), 147.1 (ArCipso), 144.3 
(CH=CH-C=O), 133.6 (ArC-OCH3), 123.3 (ArC), 113.3 (ArC-CH), 112.6 (ArC), 112.1 
(CH=CH-C=O), 61.8 (OCH3).  
MS (CI Pos.): m/z 193.1 (M+H)+; HRMS (EI Pos., TOF): m/z 192.0425 (192.0423 calcd. 
for C10H8O4 (M+)).  
(E)-5-Bromo-3-methylpenta-1,3-diene (21)7 
 
To a solution of the alcohol 13 (0.14 g, 1.4 mmol) in CH2Cl2 (3 mL) at 0 oC was 
added phosphorus tribromide (73 µL, 0.78 mmol) and the mixture was stirred at 0 °C for 
30 min. Saturated aqueous NaHCO3 and CH2Cl2 (5 mL) were added and the biphasic 
solution was separated. The aqueous layer was extracted with CH2Cl2 (2×5mL) and the 
combined extracts were dried (Na2SO4) and concentrated to provide 21 (0.16 g, 75%) as a 
brown liquid. This was used in the next step without purification. 
1H NMR (300 MHz, CDCl3): δ 6.36 (ddd, 1H, J = 17.4, 10.7, 0.8, CHCH2), 5.79 (apparent 
t, 1H, J = 8.7, CHCH2OH), 5.30 (d, 1H, J = 17.4, CHCH2), 5.12 (d, 1H, J = 10.7, CHCH2), 
4.14 (d, 2H, J = 8.7, CH2OH), 1.84 (d, 3H, J = 1.3, CH3). 
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(E)-8-Methoxy-7-((3-methylpenta-2,4-dien-1-yl)oxy)-2H-chromen-2-one (20): 
 
To a solution of the coumarin 10 (58 mg, 0.3 mmol) and bromodiene 21 (70 mg, 
0.4 mmol) in acetone (5 mL), was added Na2CO3 (54 mg, 0.4 mmol). The suspension was 
heated at 50 °C for 20 h and then cooled to room temperature. The precipitated solids were 
removed by suction filtration and the filtrate was concentrated under reduced pressure to 
obtain a yellow solid. This was purified by flash chromatography on silica gel 
(EtOAc/hexanes, 3/7) to provide unreacted 10 (24 mg, 41%) and 20 (44 mg, 79%) as a 
white solid.   
Mp: 85-88 °C.  
IR (neat): 2928, 1707, 1603, 1495, 1454, 1293, 1127, 1086, 1044, 976 cm-1.  
1H NMR (300 MHz, CDCl3): δ 7.62 (d, 1H, J = 9.5, CH=CH-C=O), 7.15 (d, 1H, J = 8.6, 
ArH), 6.85 (d, 1H, J = 8.6, ArH), 6.42 (apparent dd, 1H, J = 17.4, 10.7, CH=CH2), 6.27 (d, 
1H, J = 9.5, CH=CH-C=O), 5.76 (br t, J = 6.4, 1H, CHCH2OH), 5.28 (br d, 1H, J = 17.4, 
CH2=CH), 5.12 ( br d, 1H, J = 10.7, CH2=CH), 4.83 (d, 2H, J = 6.4, CH2-OAr), 3.99 (s, 
3H, OCH3), 1.55 (s, 3H, CH3).  
13C NMR (75 MHz, CDCl3): δ 160.9 (CO2), 155.0 (ArC-O-C=O),  148.6 (ArC-OCH3), 
143.9 (CH=CH-C=O), 140.4 (ArCipso), 138.4 (CH=CH2), 137.0 (C-CH3), 126.1 
(CHCH2O), 123.0 (ArC), 114.3 (ArC-CH), 113.9 (CH=CH-C=O), 110.5 (ArC), 66.5 (CH2-
OAr), 61.8 (OCH3), 12.6 (CH3).  
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MS (CI Pos.): m/z 273.4 (M+H)+; HRMS (EI Pos., TOF): m/z 272.1042 (272.1049 calcd. 
for C16H16O4 (M+). 
(4E,6E)-2-Hydroxy-8-((8-methoxy-2-oxo-2H-chromen-7-yl)oxy)-N-2,6-
trimethylocta-4,6-dienamide (19): 
 
To a solution of 20 (75 mg, 0.27 mmol) and 6 (20 mg, 0.13 mmol) in CH2Cl2 (3 
mL) was added the Grubbs II catalyst (2.3 mg, 2.7 × 10-3 mmol, 2 mol%) and the solution 
was heated to reflux for 22 h. The reaction mixture was then cooled to room temperature 
and concentrated under reduced pressure. The brown, gummy residue was purified by flash 
chromatography on silica gel (EtOAc/hexanes, 9/1) to provide 19 (20 mg, 41%) as a brown 
gum. 
IR (neat): 3366, 3207, 2925, 1723, 1647, 1601, 1547, 1407, 1262, 1210, 1126, 1047 cm-1 
1H NMR (300 MHz, CDCl3): δ 7.62 (d, 1H, J = 9.5, CH=CH-C=O), 7.15 (d, 1H, J = 8.7, 
ArH), 6.85 (d, 1H, J = 8.7, ArH), 6.73 (br s, 1H, NH), 6.27 (d, 1H, J = 9.5, CH=CH-C=O), 
6.22 (d, 1H, J = CH=C-CH3), 5.78 – 5.68 (m, 1H, CH-CH2), 5.68-5.65 (m, 1H, CH-CH2O), 
4.80 (d, 1H, J = 6.5, CH2O), 3.98 (s, 1H, OCH3), 2.83 (d, J = 4.9, 3H, N-CH3), 2.77 (dd, 
1H, J = 14.1, 6.8, CH2-CH), 2.44 – 2.34 (dd, J = 14.1, 5.8, 1H, CH2-CH), 2.35 (br s, 1H, 
OH), 1.85 (br s, 1H, CH3), 1.44 (s, 3H, CH3).  
13C NMR (75 MHz, CDCl3): δ 175.8 (CONH), 160.6 (CO2), 154.8 (ArC-OCH2), 148.2 
(ArC-OCH3), 143.6 (CH=CH-C=O), 138.5 (ArCipso), 137.6 (C(CH3)CH), 136.8 
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(CHCH2O), 125.1 (CHCH2), 124.1 (CHCHCH2), 122.7 (ArC), 113.9 (ArC-CH), 113.6 
(CH=CH-C=O), 110.2 (ArC), 75.5 (C-OH), 66.1 (CH2-OAr), 61.5 (OCH3), 43.6 
(CH2CH=CH), 26.2  (N-CH3), 26.0 (CH3COH), 13.1 (CH3).  
MS (CI Pos.): m/z 388.1 (M+H)+. 
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2.5 Selected 1H and 13C NMR spectra 
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Stereoselective Allylation of α-Ketoacid Derivatives for the 
Synthesis of α-Alkyl-α-Hydroxy acids 
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3.1 Introduction 
 In Chapter 1 and Chapter 2 of this thesis, the application of enantiomerically pure 
α-alkyl,α-hydroxy acid derivatives in the synthesis of selected natural products was 
presented. The efficient stereoselective synthesis of these acid derivatives has been a 
challenge for organic chemists for a long time. The asymmetric allylation of aldehydes and 
ketones is a useful synthetic tool for the preparation of enantiomerically pure α-branched 
α-hydroxy acids. A number of synthetic methods have been successfully investigated for 
the asymmetric allylation of aromatic α-ketoacid derivatives for the synthesis of 
corresponding α-alkyl,α-aryl,α-hydroxy acids.1 However, relatively few methods are 
reported for the enantioselective allylation of aliphatic α-ketoacid derivatives. The 
following discussion will provide a brief review of developments in this field. 
3.1.1 Methods for the stereoselective allylation of α-ketoacid derivatives: 
Procedures for the stereoselective allylation of α-ketoacid derivatives can be 
broadly classified as follows:  
 Allylation of chiral α-ketoesters 
 Lewis acid-mediated allylation of chiral α-ketoamides 
 Asymmetric allylation of 1,3-dioxolanones 
 Asymmetric allylation of α-ketoesters using chiral allylation reagents  
 Application of the Ireland-Claisen rearrangement 
Initial success in the allylation of α-ketoacid derivatives was obtained by the 
nucleophilic allylation of chiral auxiliary modified pyruvate esters, and amides.2 Over the 
last two decades, the application of chiral allylation reagents has proved to be a promising 
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method3 for stereoselective allylation along with the Ireland-Claisen rearrangement.4 Most 
of the methods focus on the enantioselective allylation of aromatic α-ketoacid derivatives. 
Since most of the work described in this thesis is based on the stereoselective allylation of 
a chiral pyruvic acid derivative, the following sections summarize the reported 
enantioselective allylations of aliphatic α-ketoacid derivatives. 
3.1.1.1 Allylation of chiral α-ketoesters: 
Ojima and co-workers5 reported the asymmetric allylation of (−)-menthyl pyruvate 
1 and phenyl glyoxylate. The treatment of 1 with allyltrimethyl silane and titanium chloride 
at −75 °C afforded the hydroxy acid derivative 2 in good yield and as a 3.4:1 mixture of 
diastereomers. An alkaline hydrolysis of 2 provided the α-hydroxy acid 3 (55% ee) and     
(−)-menthol 4 was recovered (Scheme 3.1). A similar reaction employing an allyl Grignard 
reagent did not show any selectivity. 
 
Scheme 3.1 
In a later study, Whitesell2f and Fang2g independently reported a modification of 
the method reported by Ojima.5 Instead of (−)-menthyl pyruvate, 8-phenymenthyl pyruvate 
was subjected to an ene reaction. An earlier study by Whitesell6 had indicated that (−)-8-
phenylmenthol provides good selectivity in the alkylation of pyruvates. Treatment of            
(−)-8-phenylmenthyl pyruvate 5 with hex-1-ene furnished 6 as a single diastereomer 
(Scheme 3.2). On the other hand, Fang and co-workers examined the allylation of 5 with 
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allyltrimethyl silane as the nucleophile and titanium tetrachloride as the Lewis acid to 
obtain 7 as a single diastereomer (Scheme 3.2). In both reactions, it is assumed that the 
phenyl group in the auxiliary blocks the Re face of the ketone, in the s-cis rotamer of the 
α-ketoester which results in the addition of nucleophiles from the Si-face to form                 
(S)-α-hydroxy esters selectively. A drawback of the Whitesell protocol is formation of a 
side product resulting from aldol reaction of 5 with itself. Other limitations of the 
methodology are the multistep synthesis of 8-phenylmenthol and the high cost of (+)-8-
phenylmenthol which is required for preparing the enantiomeric hydroxy acids.  
 
Scheme 3.2 
Due to these limitations, the Whitesell group developed a better alternative for     
(+)-8-phenylmenthol.7 Thus, the ene reaction of pyruvate ester 9, made from (+)-trans-2-
phenylcyclohexanol (8), with hex-1-ene in the presence of titanium tetrachloride afforded 
10 in good yield (85%) and stereochemical control (up to 91% de). However, a significant 
amount of the cyclic product 11 was formed in this reaction (Scheme 3.3).  
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Scheme 3.3 
Allylation of 9 with allyltrimethylsilane provided 12 in excellent diastereomeric 
excess (>99%) and the corresponding tetrahydrofuran byproduct 13 was formed only in 
trace amounts (Scheme 3.4). The ester 12 was further converted to (+)-citramalic acid 15 
in 96% enantiomeric excess.  
 
Scheme 3.4 
Notably, selectivity in the formation of the new stereocenter is reversed in this 
method compared to the allylation of (−)-8-phenylmenthyl pyruvate. It is suggested that 
the phenyl ring in the (−)-8-phenylmenthol acts as a π-donor and shields one face of the 
chelated α-ketoester 5 which results in the selective addition of the nucleophile to the 
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carbonyl ketone resulting in the formation of 6 (91% de, Figure 3.1).7 The authors suggest 
that a similar interaction is less likely with trans-2-phenylcyclohexanol.7 However, an 
explanation for the origin of selectivity in the formation of 10 (99% de, Figure 3.1) was 
not provided. 
 
Figure 3.1 Origin of selectivity in allylation of 5 and 9. 
3.1.1.2 Asymmetric allylation of chiral α-ketoamides: 
 The first asymmetric Barbier-type allylation of α-ketoamides in aqueous medium was 
reported by Waldmann.2c Treatment of 17 with allyl bromide in the presence of zinc and 
pyridinium p-toluenesulfonate in THF-water (2:1) afforded a mixture of diastereomers 18 
and 19 in high yields and with moderate stereoselectivities (Scheme 3.5).  
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Scheme 3.5 
       Aliphatic α-ketoacids are less reactive compared to aromatic ketoacids and 
underivatized allyl halides react faster compared to substituted allyl halides. The products 
were obtained with diastereoselectivity up to 6:1. This level of selectivity was obtained 
only with proline benzyl ester as the auxiliary and other amino esters were not suitable 
auxiliaries for this reaction. 
       In 1995, Kim and co-workers reported the highly selective asymmetric allylation of  
α-ketoamides derived from (S)-indoline-2-carboxylic acid.8 Previously, they had 
demonstrated that (S)-indoline derivatives are excellent chiral auxiliaries in the asymmetric 
alkylation of aldehydes9 and the asymmetric reduction of ketones.10 Allylation of 
pyruvamide 20, derived from (S)-indoline-2-carboxylate, with allyltributyl stannane in the 
presence of Lewis acids such as TiCl4 and SnCl4 afforded the tertiary homoallylic alcohol 
21, which readily underwent lactonization to form 22. Depending on the allylation reagent 
and the Lewis acid, the diastereomeric excess of 22 varied from 80-94% (Scheme 3.6).  
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Scheme 3.6 
      To avoid lactonization, 23 (with a t-butyl dimethylsilyloxymethyl moiety in place of 
the ester in 20) was prepared, and used in the allylation to obtain 24 with very high 
diastereoselectivity (Scheme 3.7). The product could be hydrolyzed to obtain (R)-2-
hydroxy-2-methyl-4-pentenoic acid 3 (>99% ee). The proposed transition state suggests 
that conformer 25 is more favorable compared to 26 due to the repulsion between the 
methyl group and the phenyl ring. Since the Re face of the ketone in 24 is shielded by the 
R group in the auxiliary, addition from the less-hindered Si-face of the ketone provides the 
observed product (Figure 3.2). 
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Scheme 3.7 
 
Figure 3.2 Proposed transition state for the allylation of proline-based pyruvamide. 
       Diastereoselective allylation of α-ketoamides derived from Oppolzer’s sultam11 was 
reported by Jurczak.12 N-Methyl-(2R)-bornane-10,2-sultam 28 was prepared from 
Oppolzer’s sultam 27, and was treated with a variety of allylation reagents. These included 
allyl bromide with zinc dust, and allyltrimethyl silane in the presence of Lewis acids 
(Scheme 3.8). The best results in terms of stereoselectivity (29:30 = 93:7) was obtained 
with allylmagnesium chloride. 
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Scheme 3.8 
      In 2004, diastereoselective allylation of camphorpyrazolidinone-derived α-ketoamides 
was reported by Chen and co-workers.2a Allylation of 32-34 (Scheme 3.9) was carried out 
with allyltributyl tin in the presence of a Lewis acid. The chiral auxiliary 31 was treated 
with the α-ketoacid chloride to obtain chiral α-ketoamides 32-34. Sn(OTf)2, Zn(OTf)2, 
Sc(OTf)3, and Eu(OTf)3 were examined as Lewis acids for the allylation of 33 and the best 
results in terms of stereoselectivity were obtained with Zn(OTf)2 (37:38 = 9:1). For the 
substrate 34, Sn(OTf)2 provided 39 and 40 with moderate selectivity (39:40 = 83:17). 
Scheme 3.9 
       In the initial studies, camphorpyrazolidinone phenylglyoxamide 32 was used as a 
model compound.2a In the absence of Lewis acid, treatment of 32 with allyltributyltin did 
not provide any of the desired product. The use of 1 eq. Eu(OTf)3 as the Lewis acid afforded 
50% conversion in CH3CN with moderate diastereoselectivity (35:36 = 72:28) and the use 
of Zn(OTf)2, instead of Eu(OTf)3, afforded a 93% yield of 35 with good diastereoselectivity 
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(35:36 = 94:6) as indicated by 1H NMR spectroscopy. The absolute configuration at the 
newly-generated stereocenter was assigned as R by X-ray crystallography. The scope of 
the method was examined with camphorpyrazolidinone pyruvamide 33 and 
ketobutyramide 34. Pyruvamide 33 afforded the desired product with moderate 
diastereoselectivity in the presence of Zn(OTf)2 (37:38 = 9:1) and Sn(OTf)2 (37:38 = 
79:21). However, the use Eu(OTf)3 resulted in a reversal of selectivity (37:38 = 26:74). The 
stereochemical outcome of the reaction was reasoned to be due to the different modes of 
coordination of the metal ion to the α-ketoamide moiety (Figure 3.3).  
 
Figure 3.3 Transition state models resulting in the opposite stereochemistry. 
      In the case of Lewis acids, such as Zn(OTf)2 and Sn(OTf)2 , dicoordination of the metal 
with the carbonyl oxygens favors the s-cis conformer 42 of the ketoamide, thereby 
promoting addition to the Si face of the ketone under steric control to afford the observed 
product (Figure 3.2). In the case of Eu(OTf)3, mono-coordination of the metal to the 
carbonyl oxygen is favored and the s-trans conformer in 41 is predominant, resulting in a 
reversal of the selectivity, with the nucleophile approaching from the less-hindered Re face 
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of the ketone. However, this hypothesis contradicts the results obtained with 
camphorpyrazolidinone phenylglyoxamide 32, since the treatment of 32 with Eu(OTf)3  
affords 36 as the major product. 
3.1.1.3 Asymmetric allylation of 1,3-dioxolanones: 
In the previous section, asymmetric allylation of chiral α-ketoesters, where 
nucleophilic addition of an allyl group occurs at the carbonyl carbon, was presented. The 
following section describes a complementary strategy in which the alkylation of glycolic 
acid-derived enolates with allylic electrophiles is examined. 
  Frater and co-workers,2d reported the allylation of 1,3-dioxolan-4-one derived from    
(−)-S-lactic acid (43) and (+)-S-mandelic acid (44) (Scheme 3.10). The 1,3-dioxolanones 
44 and 45, obtained from lactic acid and mandelic acid respectively, by condensation with 
pivalaldehyde, were treated with LDA and allyl bromide to provide 46 and 47 (46:47 = 
98:2) and 48 and 49 (48:49 = 98:2). Hydrolysis of 46-49 to the corresponding hydroxy 
acids was not reported. 
 
 
Scheme 3.10 
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  In a similar study, Seebach reported the asymmetric allylation of 1,3-dioxolanones 
derived from (S)-lactic acid (43), (S)-α-isovaleric acid (50), (±)-thiolactic acid (51), and  
(±)-thiomalic acid (52).13 In the methods developed by Frater and Seebach, the original 
stereocenter in the hydroxy acid is destroyed to form an enolate which is still chiral due to 
the acetal stereocenter. This stereocenter is believed to direct the electrophilic addition.2d,13 
The Seebach group successfully obtained the 1,3-dioxolanones 45 and 56-58 as a mixture 
of diastereomers which were separated by recrystallization from ether/pentane and the cis 
diastereomer was used further (Scheme 3.11). 
 
Scheme 3.11 
        Enolate generation from cis dioxolanones using LDA or LHMDS, followed by the 
addition of allyl bromide resulted in alkylation products with greater than 95% 
diastereomeric excess (Scheme 3.12). The authors propose that addition of the electrophile 
to the enolate proceeds from the Re face, that is, the face opposite to the t-butyl group. 
Notably, although 46, 60 and 61 are potential precursors to the corresponding free α-
hydroxy acids, upon subsequent hydrolysis, this conversion was not reported in this study. 
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Scheme 3.12 
  Application of (1S)-(+)-N,N-diisopropyl-10-camphorsulfonamide as an auxiliary was 
demonstrated in the enantioselective synthesis of α-hydroxy acids by Uang and co-
workers.14  Condensation of 63 with excess rac-lactic acid in the presence of BF3•OEt2 
resulted in the formation of 1,3-dioxolanone 64 as a single diastereomer (Scheme 3.13). 
The configuration of the new stereocenter was determined to be S using X-ray 
crystallography. Treatment of 64 with LDA at −100 °C followed by the addition of allyl 
bromide afforded 65 with excellent diastereoselectivity (98%). The alkylation of the 
enolate is believed to occur from the less hindered Si face. The configuration at the                 
α-carbon was determined to be R by X-ray crystallography. The enantiomerically-enriched 
α,α-dialkyl,α-hydroxycarboxylic acid 3 was obtained by hydrolysis of 65 in methanol and 
aqueous 2 M NaOH, followed by acidification. The chiral auxiliary 62 was also recovered 
in high yield (92-96%).  
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Scheme 3.13 
 In 2006, Xu and co-workers2e demonstrated the application of Frater’s2d and 
Seebach’s protocols13,15 (Scheme 3.12) in the synthesis of α-alkyl isoserines by asymmetric 
allylation of D- and L-malic acids. Isoserine derivatives are β-amino acids which are part 
of biologically-active natural products such as bestatin,16 amatatin,16 norstatin,17 and 
taxol.18 A variety of methods are available for the synthesis of β-substituted isoserines in 
optically active form.19 However, only a few studies have been conducted on the synthesis 
of chiral, α-alkyl isoserines.20 In a study by Xu,2e the dioxolanone 67 was obtained from 
the condensation of  D-malic acid (66) and pivalaldehyde. Treatment of 67 with LHMDS, 
followed by addition of allyl bromide in THF provided (2R,4R) 68 with >98% de. The acid 
68 was further converted to the carbamate (2R,4R) 69. Hydrolysis of 69 in hydrochloric 
acid afforded the hydrochloride salt of 70 which was converted into the free β-amino acid 
(98% ee) by reaction with propylene oxide (Scheme 3.14). 
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Scheme 3.14 
Kellogg21 reported an enzyme-catalyzed hydrolysis to resolve the mixture of 
racemic α-substituted α-hydroxy ester 74 using pig lever esterase (PLE). The α-substituted 
α-hydroxy ester 74 was synthesized from the corresponding α-hydroxy acid. Reaction of 
racemic 71 with acetone provided the dioxolanone 72. Alkylation of 72 (LDA, allyl 
bromide) afforded dioxalonone 73, hydrolysis of which provided the racemic α-hydroxy 
ester 74. The ester 74 was treated with PLE-S 3.1.1.1 and PLE-A in 0.05 M phosphate 
buffer at pH 8. Reactions were terminated when the conversion was 20-50% complete, and 
optically active acid product 3 and unreacted ester 75 were isolated in good yields (Scheme 
3.15). In related studies,21 moderate to good enantiomeric excess (49 to 86%) was observed 
for the enzymatic hydrolysis of aromatic esters, but not for aliphatic α-hydroxy,α-
allylesters. 
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Scheme 3.15 
3.1.1.4 Asymmetric allylation of α-ketoesters using chiral allylation reagents: 
Asymmetric allylation of α-ketoacid derivatives using chiral allylation reagents has 
also been investigated for the synthesis of homoallylic alcohols. For example, Trost and 
co-workers presented a nucleophilic allylation of oxalactim 78 for the synthesis of 
homoallylic amides (Scheme 3.16).22 (E)-1-Bromo-5-methylhexa-2,4-diene was the only 
aliphatic substituent used along with a variety of aromatic substituents. The amide 81 was 
obtained in 89% ee. 
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Scheme 3.16 
On the other hand, Yang reported an enantioselective intramolecular ene reaction 
of an unsaturated α-ketoacid.23 (R,R)-Ph-pybox (83) was employed as a chiral ligand along 
with the range of Lewis acids to obtain 84 with moderate to very good diastereoselectivity 
(54-91% de, Scheme 3.17). 
 
Scheme 3.17 
 However, there are very few examples reported for the enantioselective allylation 
of α-ketoacid derivatives using 1) a Lewis acid with chiral ligands23 or 2) an allylating 
metal reagent combined with chiral ligands.3a,22 A report by Mukaiyama3a employs a chiral 
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tin reagent for the enantioselective allylation of α-ketoesters (Scheme 3.18). A divalent 
tin(II) catecholate 86 was treated with allyl bromide in the presence of a dialkyl tartrate, 
DBU and a catalytic amount of CuI to obtain the highly reactive allyl tin reagent 88 in situ 
(Scheme 3.18). Reactions of 88 with a variety of pyruvate esters 89 a-e proceeded with 
moderate to high enantioselectivity (60-95% ee, Table 3.1). However, allylation of benzyl-
3-methyl butyrate proceeded with only 30% ee (Table 3.1, entry 5). 
Scheme 3.18 
Table 3.1 Survey of pyruvic esters for the asymmetric allylation with 88 
Entry 89 R1 R2 90 Yield (%) % ee 
1 a Me Ph a 81 60 
2 b Me Bn b 87 95 
3 c Me 4-ClC6H4 c 72 95 
4 d Me 4-OMeC6H4 d 87 95 
5 e i-Bu Bn e 52 30 
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In 2007, Feng reported the application of a C2-symmetric N,N’-dioxide-In(III) 
complex 92 in the allylation of α-ketoesters.3b Aromatic substrates afforded excellent 
enantioselectivities. However, the allylation of the aliphatic substrate 91 proceeded with 
only moderate selectivity (Scheme 3.19).  
 
Scheme 3.19 
3.1.1.5 Ireland-Claisen rearrangement of α-ketoesters in the synthesis of            
α-hydroxy acids: 
Woerpel and co-workers reported the synthesis of α-hydroxy acids by silylene 
transfer to allylic α-ketoesters.24 This method has enabled a stereoselective synthesis of     
α-hydroxy acids possessing two contiguous stereocenters. The treatment of α-ketoester 94 
with a silacyclopropane 95 and AgOTs in toluene provided silalactone 98. Treatment of 98 
with HF
.
pyridine provided the pure α-hydroxy acid 99 exclusively (> 97% dr). The reaction 
is believed to proceed through a silacarbonyl ylide 96, which undergoes a 6π-
electrocyclization to form a silylketene acetal 97 which then undergoes the Ireland-Claisen 
rearrangement to provide the silalactone 98 (Scheme 3.20). 
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Scheme 3.20 
Enantiomerically enriched α-ketoesters showed excellent diastereoselectivity in 
this protocol. The treatment of 100 with 95 and AgOTs followed by addition of HF.pyridine 
resulted in the formation of α-hydroxy acid 101 as a single enantiomer (Scheme 3.21). 
 
Scheme 3.21 
Johnson and co-workers reported a synthesis of α-hydroxy acids via sequential 
Brook and Ireland-Claisen rearrangement of silylglyoxylates.4 Addition of 
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methylmagnesium bromide to silyl glyoxylates 102 and 103 in the presence of TMSOTf 
generates the corresponding tetrahedral intermediate which undergoes a [1,2]-Brook 
rearrangement. The resulting enolate then undergoes an Ireland-Claisen rearrangement and 
products 104 and 105 are obtained as a mixture of diastereomers (Table 3.2). Similarly, 
treatment of 102 and 103 with an organozinc nucleophile, such as allylzinc bromide, 
afforded the α-hydroxy acid TBS ethers 106 and 107 respectively as a mixture of 
diastereomers (Scheme 3.22, Table 3.2). The use of an organozinc reagent seems to provide 
products that retain the TBS protection, but this aspect has not been explained in this study. 
 
Scheme 3.22 
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Table 3.2 Reaction of Grignard and organozinc reagents with 102 and 103 
Entry Silyl glyoxylate Nucleophile Product   Yield (%) dr 
1 102 MeMgBr/TMSOTf 104  64 5.7:1 
2 103 MeMgBr/TMSOTf 105  65 4.9:1 
3 102 allylZnBr 106  57 8:1 
4 103 allylZnBr 107  67 6:1 
 
 The proposed mechanism of the reaction is described in Scheme 23. The addition 
of a nucleophile to the ketone in 108 generates the tetrahedral intermediate 109. A 1,2 shift 
of the silyl group from the carbon to oxygen (Brook rearrangement) generates the Z-enolate 
110 which then undergoes a [3,3] Sigmatropic rearrangement leading to the observed 
product 113. The diastereoselectivity depends upon the equilibrium between the Z-enolate 
110 and the E-enolate 112 via the intermediate 111.  The major product of the reaction is 
obtained from the Z-enolate. 
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Scheme 3.23 
3.2 Introduction to the present work 
3.2.1 Asymmetric allylation of morpholinones derived from chiral amino alcohols. 
The Pansare group has developed the synthesis of enantiomerically pure α-allyl, α-
hydroxyamides 120 (Scheme 3.24) by highly diastereoselective allylation of ephedrine 
derived morpholinones 118.25 
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Scheme 3.24 
 This methodology has been utilized as a key component in the synthesis of 
biologically active natural products and natural product motifs such as (−)-quinic acid,26 
medium sized oxacycles,27 (R)-homocitricacid lactone28 and (+)-8-O-
methylaphanorphine.29 These syntheses use the α-hydroxy amide 120 a as a chiral starting 
material.26-28,30 
This ephedrine-based method provides two major advantages 1) excellent 
diastereoselectivity in the allylation step is obtained and 2) α-hydroxy amides were 
obtained in good overall yield. The drawback of this method is that the removal of the 
ephedrine portion is achieved by reductive cleavage, which results in the destruction of 
ephedrine. Also, ephedrine has been declared a controlled substance and it is no longer 
commercially available. Therefore, efforts were made towards identifying other amino 
alcohols which can replace ephedrine as the chiral starting material. 
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The objectives of this study were: 1) to identify and utilize a chiral amino alcohol 
for the synthesis of morpholinediones which can be used as a replacement for the ephedrine 
based morpholinedione and 2) to identify an amino alcohol which can be recovered at the 
end of the synthesis, thus functioning as a chiral auxiliary rather than a chiral starting 
material. 
3.2.2 Previous investigations of chiral amino alcohols within the Pansare group 
3.2.2.1 Studies with diphenylprolinol as a potentially recoverable amino alcohol: 
Diphenylprolinol was prepared from (S)-proline 121 following the previously 
reported procedure by Kanth and Periasamy.31 Protection of the amine in 121 as the ethyl 
carbamate gave 122 (Scheme 3.25). Conversion of the carboxylic acid to a methyl ester 
followed by treatment with phenylmagnesium bromide provided the alcohol 123. 
Hydrolysis of the carbamate provided the amino alcohol 124. 
 
Scheme 3.25 
Treatment of amino alcohol 124 with ethyl oxalyl chloride gave the morpholine 
dione 125. Treatment of dione 125 with propylmagnesium bromide furnished hemiacetal 
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126 as a mixture 3:1 mixture of diastereomers. Allylation of 126 using 
TiCl4/allyltrimethylsilane at −40 °C furnished 127 as 1.7:1 mixture of diastereomers 
(Scheme 3.26). The poor diastereoselectivity for the allylation reaction indicated that 
diphenylprolinol was not a good auxiliary for the morpholinedione-based synthesis of α-
hydroxy acids. Consequently, cleavage of the benzylic C-O bond in 127, in order to recover 
124, was not examined. 
 
Scheme 3.26  
3.2.2.2 Studies with non-recoverable amino alcohols: 
The amino alcohol 130 was prepared from (S)-phenylglycine 128 following a 
previously reported procedure (Scheme 3.27).32 Thus, N-formylation of (S)-phenylalanine 
(128) provided 129. Reduction of the amide as well as carboxylic acid with LiAlH4 
provided the required amino alcohol 130 in excellent yield (99%).33 
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Scheme 3.27  
Amino alcohol 130 was treated with ethyl oxalyl chloride to obtain dione 131. 
Treatment of 131 with ethylmagnesium bromide provided the hemiacetal 132 as a 3:1 
mixture of diastereomers. The allylation of 132 with TiCl4 and allyltrimethylsilane 
provided 133 as 1:1 mixture of diastereomers (Scheme 3.28). This result suggested that the 
stereocenter adjacent to the oxygen in the ephedrine-derived morpholine system may be 
important for good stereoselectivity in the allylation step and the lack of 1,3 stereocontrol 
in 132 could be responsible for the unselective allylation.33 
 
Scheme 3.28   
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With this reasoning in mind, the amino alcohol 136 was prepared from (S)-mandelic 
acid (134) according to the procedure reported by Davis and co-workers.34 Reaction of (S)-
mandelic acid (134) with acetone generated the derivative 135 (Scheme 3.29). Treatment 
of 135 with methylamine in ethanol gave N-methylmandelamide, which was reduced with 
LiAlH4 to obtain the amino alcohol 136.33 
 
Scheme 3.29 
Amino alcohol 136 was converted to the dione 137 by treatment with ethyl oxalyl 
chloride. Treatment of dione 137 with ethylmagnesium bromide provided the hemiacetal 
138 as a 5:1 mixture of diastereomers (Scheme 3.30). Allylation of 138 using TiCl4 and 
allyltrimethylsilane provided 139 as a 2:1 mixture of diastereomers.33 
 
Scheme 3.30 
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The higher diastereoselectivity in the allylation of 138 (2:1 dr) compared to 132 
(1:1 dr) suggested that 1,3-stereocontrol does play a role in the allylation of amino alcohol-
derived morpholinones. However, since the stereoselectivity is still far less than that seen 
for the ephedrine-derived system, 1,3-stereocontrol is obviously not the only factor 
controlling the diastereoselectivity. Clearly, the 2,3-disubstituted morpholinone motif 
obtained by using ephedrine is necessary for high diastereoselectivity in the allylation step. 
The dialkyl morpholinones 133 and 139 were subjected to dissolving metal 
reduction to obtain α-hydroxy amides 140 and ent-120 respectively (Scheme 3.31). The 
configuration of the newly generated stereocenter in dialkylmorpholinone 139 was 
assigned as S based on the specific rotation of the amide ent-120 ([]23D = −6.5 (c 1.7, 
H2O)),33 which indicated an excess of the ‘S’ enantiomer  ([]23D = +16 (c 1.7, H2O) for 
(R)-120).25 
 
Scheme 3.31 
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3.3 Present work 
3.3.1 Investigation of potentially recoverable amino alcohol substitutes for 1R,2S-  
            ephedrine:  
The studies described above indicated that a 2,3-disubstituted morpholinone was 
required and hence we decided to examine the diaryl alaninols 141 and 142 as substitutes 
for ephedrine. At the outset, we assumed that the synthesis of the dialkylmorpholinones 
145 and 146 could be achieved from diones 143 and 144 respectively, hopefully with 
stereoselectivities similar to those obtained from the ephedrine derived morpholinedione 
117. The morpholinediones in turn, could be obtained from the respective amino alcohols 
141 and 142 (Scheme 3.32) using procedures similar to those employed for the ephedrine 
based morpholinedione. 
 
Scheme 3.32 
Since diphenylmethyl ethers are known to be cleaved under acidic conditions,35 it 
seemed reasonable that, in the presence of an aqueous acid, cleavage of the benzylic C-O 
bond in 145 and 146 would occur. This could generate either 147 or 149 (Scheme 3.33), 
which would ultimately provide the required α-hydroxy acid 150 through the intermediates 
148 or 150. The amino alcohols 141 or 142 would therefore be recovered.  
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Scheme 3.33 
3.3.2 Investigation of potentially recoverable chiral amino alcohols derived from                      
            (S)-alanine: 
The diarylalaninols 141 and 142 were prepared from (S)-alanine methyl ester 
hydrochloride (152, Scheme 3.34). Reaction of 152 directly with four equivalents of the 
phenylmagnesium bromide provided the corresponding tertiary alcohol 153. Alternatively, 
conversion of 152 to the free base and subsequent reaction with three equivalents of             
p-anisylmagnesium bromide provided 154. N-Formylation of 153 and 154 using acetic 
formic anyhydride followed by the reduction of the formyl group using LiAlH4 furnished 
the required amino alcohols 141 and 142 respectively. 
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Scheme 3.34 
Treatment of 141 with oxalyl chloride provided the dione 143 (46%, Scheme 3.35). 
Treatment of 143 with propylmagnesium bromide gave 157 as a 4:1 mixture of 
diastereomers (86%). The hemiacetal 157 was allylated using BF3.OEt2 resulting in the 
formation of 158 as a single diastereomer in low yield (22%, Scheme 3.35).33 Allylation of 
157 using TiCl4 as the Lewis acid (−78 °C to −40 °C) provided 158 in higher yield (54%) 
but lower diastereoselectivity (5:1 dr). 
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Scheme 3.35 
Interestingly, better selectivity in the allylation was observed with the replacement 
of the propyl group by an isopropyl group. Treatment of 143 with isopropylmagnesium 
bromide provided the hemiacetal 159 as a 4:1 mixture of diastereomers (87%, Scheme 
3.36). Allylation of 159 using TiCl4 and allyltrimethyl silane (−78 °C to −40 °C) provided 
the dialkyl morpholinone 160 as a 9:1 mixture of diastereomers (58%). Notably, this 
dependence of the stereoselectivity of allylation on the steric requirements of the alkyl 
group in the hemiacetal is not observed in the corresponding ephedrine-derived 
hemiacetals.25 
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Scheme 3.36 
In a related set of experiments, the treatment of 142 with oxalyl chloride provided 
the dione 144 (58%). Treatment of 144 with isopropylmagnesium bromide gave the 
hemiacetal 161 as a 4:1 mixture of the diastereomers. Allylation of 161 using BF3.OEt2 and 
allyltrimethylsilane furnished the dialkylmorpholinone 162 (27%, Scheme 3.37) as a single 
diastereomer. Changing the Lewis acid to TiCl4 furnished 162 in higher yield and 
diastereoselectivity (55%, single diastereomer).  
 
Scheme 3.37 
Notably, despite the structural similarity between 161 and 159, the 
diastereoselectivity of their allylation reactions is very different (10:1 for 160, and a single 
diastereomer for 162). The reasons for this difference are not known at present.  
Since one of the objectives of this study was recovery of the starting amino alcohols 
141 and 142, conversion of the morpholinones 160 and 162 to the α-hydroxy acid 150 and 
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141 or 142 was attempted under a variety of conditions that were expected to facilitate 
cleavage of the benzylic C-O bond.36 Unfortunately, treatment of morpholinone 160 or 162 
with protic acids resulted either in no reaction, even after prolonged exposure, or complete 
decomposition depending on the acid that was employed. These results are summarized in 
Table 3.3-3.5. 
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Table 3.3 Attempted hydrolysis of the morpholinones 160 and 162 under acidic conditions. 
  
No Reagents Temperature  
(°C) 
Time 
(h) 
Result 
1 HCl (2 M), dioxane 100 10 160/162 
2 H2SO4 (cat.), H2O 100 24 160/162 
3 H2SO4  (cat), HO(CH2)2OH 160 96 160/162 
4 H2SO4 (3 M), dioxane rt 4 Decomposition 
5 HBr (30%wt in AcOH) rt 18 Decomposition 
6 HBr (48%), dioxane rt 20 Decomposition 
7 BF3.(OEt)2, CH2Cl2 rt 72 Decomposition 
8 CF3COOH, CH2Cl2 rt 48 160/162 
9 CF3COOH, CH2Cl2 55 2 160/162 
10 CuBr, dioxane:H2O (1:2) 60 120 160/162 
11 HCl (0.1 M)a 150 35 160/162 
12 HCl (2.5 M), dioxane a 150 5 160/162 
13 HCl (2.5 M), dioxane a 175 10 decomposition 
14 H2SO4 (1.0 M), dioxane a 150 10 decomposition 
          a: reactions carried out under microwave heating 
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The feasibility of either the reduction or the hydrolysis of the amide linkage in the 
morpholinones 160 and 162 was next investigated. It was reasoned that the problems 
encountered in the acidic hydrolysis of 160 and 162 could be overcome by prior ring 
opening by basic hydrolysis of the amide to provide acyclic diaryl ethers which may be 
easier to cleave under acidic conditions. However, these attempts at ring-opening were also 
unsuccesful (entries 1-3, Table 3.4). As an alternative partial reduction of the amide to a 
hemiaminal was also evaluated. However, treatment of the morpholinones 160 or 162 with 
LiAlH(OEt)3 at room temperature resulted in decomposition of the starting material. The 
treatment of morpholinones with LiAlH4 at ambient temperature on the other hand resulted 
in the recovery of the morpholinones. The outcome of this reaction did not change after 
prolonged heating, and studies with other reducing reagents also did not show positive 
results.  The results of these studies are summarized in Table 3.4. 
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Table 3.4 Attempted basic hydrolysis and reduction of the amide in the morpholinone 160 
and 162. 
No Reagent Temperature (°C) Time (h) Result 
1 t-BuOK, H2O, ether 100 12 160/162 
2 KOH, ethanol 85 8 160/162 
3 KOH, OH(CH2)2OH 200 8 160/162 
4 LiAlH(OEt)3, ether rt 12 Decomposition 
5 LiAlH4,  THF rt 24 160/162 
6 LiAlH4,  THF 80 30 Decomposition 
7 Tf2O, pyridine, Red Al, 
THF 
rt 20 160/162 
8 LiH2NBH3, THF rt 18 160/162 
 Basic hydolysis of the amide in 161 and 162 under microwave heating was 
examined, but these studies were also unsuccessful (Table 3.5). 
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Table 3.5 Attempted basic hydrolysis of the morpholinones 161 and 162 under microwave   
heating.  
No Reagent Temperature (°C)  Time 
(min) 
result 
1 KOH (2.0 M), ethanol 130 10 160/162 
2 KOH (2.0 M), ethanol 150 15 160/162 
3 KOH (2.0 M), ethanol 175 15 160/162 
4 KOH (2.0 M), ethanol 200 15 decomposition 
5 Powdered KOH, HO(CH2)2OH 200 20 160/162 
 
These results suggest that the morpholinone ring in 160 and 162 is very stable and 
ring-opening under conventional C-O and C-N bond cleavage conditions is challenging. 
Notably, the ethereal oxygen in these rings is flanked by quaternary carbons which may 
contribute to the stability of the C-O bonds under acidic conditions. Similarly, the carbonyl 
group in the amide may also be unreactive toward nucleophilic addition reactions which 
would involve the approach of nucleophiles over the morpholine ring. This approach may 
be disfavoured by the quaternary centres. 
 Fortunately, the morpholinones 158, 160 and 162 were readily cleaved under 
dissolving metal reduction conditions (Na/NH3, THF, −78 °C) to provide the corresponding 
α-hydroxy amides 120c and 120d (Scheme 3.38). The configuration of the newly formed 
stereocenter in 158, 160 and 162 was designated as R on the basis of the specific rotation 
of the amides (amide 120c: [α]D25 = +21.7 (c 1.9, CHCl3); lit.25 [α]D25 = +30 (c 1.9, CHCl3) 
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for the R enantiomer. Amide 120d obtained from 160: [α]D25 = +7.2 (c 1.6, CHCl3), and  
amide 120d obtained from 162: [α]D25 = +9.6 (c 1.6, CHCl3); lit.25 [α]D25 = +9.0 (c 1.6, 
CHCl3) for the R enantiomer). 
 
Scheme 3.38 
3.3.3 Conclusions 
 It was determined that the 2,3-disubstituted morpholine motif is essential for good 
stereoselectivity in the allylation reactions at C-6 of these morpholinones. (S)-Alanine-
derived diarylmorpholinediones 143 and 144 have provided an alternative to the 
corresponding, ephedrine-derived morpholinedione. Although the attempts to recover the 
chiral amino alcohol were unsuccessful, the amino alcohols 141 and 142 can certainly be 
used as substitutes for ephedrine as a chiral starting material in the synthesis of α-hydroxy 
acid derivatives. However, the reason morpholinone 161 shows better selctivity compared 
to the morpholinone 159 is still unclear. Studies aimed at understanding the origin of 
stereocontrol and on the recovery of the amino alcohol at the end of the α-hydroxy acid 
synthesis are ongoing in the Pansare group. 
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3.4 Experimental section 
General experimental methods: 
 All commercially available reagent were used without purification. All reactions 
requiring anhydrous conditions were performed under an atmosphere of dry nitrogen using 
oven dried glassware. Dichloromethane and tetrahydrofuran were distilled from CaH2 and 
sodium/benzophenone respectively. Commercial precoated silica gel plates were used for 
TLC. Silica gel for column chromatography was 230-400 mesh. All melting points are 
uncorrected. Optical rotations were measured at the sodium D line on a digital polarimeter 
at ambient temperature. 
(S)-2-Amino-1,1-diphenylpropan-1-ol (153): 
 
A dry, 250 mL, three-necked, round bottom flask, equipped with a reflux 
condenser, magnetic stirring bar, and nitrogen gas inlet, was charged with magnesium 
turnings (3.26 g, 0.13 mol). The flask was fitted with a rubber septum and charged 
sequentially via syringe with THF (40 mL) and bromobenzene (14.2 mL, 0.13 mol) and a 
crystal of iodine was added. The rubber septum was immediately replaced with a stopper 
and stirring was initiated. Within 5 min, an exothermic reaction initiated and the mixture 
began to reflux spontaneously. The mixture was then stirred for an additional 2 h (until all 
of the magnesium reacted) without external heating or cooling. The resulting solution was 
added dropwise to an ice-cooled suspension of s-alanine methyl ester (152) (3.00 g, 38.0 
mmol) in THF (20 mL) over a period of 30 min. The mixture was stirred at ambient 
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temperature for 16 h. Saturated, aqueous ammonium chloride solution (60 mL) was then 
added, and the mixture was stirred vigorously until the white precipitate disappeared. The 
resulting solution was extracted with ethyl acetate (3×100 mL). The combined ethyl acetate 
layers were dried and concentrated under reduced pressure to afford the crude product as a 
yellow gum. This was dissolved in 1M aqueous HCl solution (20 mL) and the resulting 
solution was extracted with ethyl acetate (2×50 mL). The aqueous layer was cooled (<5 
oC), basified with sodium hydroxide pellets (pH = 9) and then extracted with ethyl acetate 
(3×50 mL). The combined organic layers were dried (Na2SO4) and concentrated under 
reduced pressure to provide 153 (4.4 g, 90%) as a yellow foam.  
IR (neat): 3388, 3064, 2980, 1651, 1445, 1174, 966 cm-1.  
1H NMR (300 MHz, CDCl3): δ 7.64-7.63 (m, 1H, ArH), 7.62-7.58 (m, 1H, ArH), 7.49-
7.44  (m, 2H, ArH), 7.36-7.23 (m, 4H, ArH), 7.22- 7.12 (m, 2H, ArH), 4.17- 4.11 (q, 1H, 
J = 6.3, CHCH3), 0.94 (d, 2H, J = 6.3, CH3CH).  
13C NMR (126 MHz, CDCl3) δ 146.9 (ArCipso), 144.8 (ArCipso), 128.4 (ArC), 128.0 (ArC), 
126.7 (ArC), 126.4 (ArC), 125.9 (ArC), 125.5 (ArC), 78.5 (C-OH), 51.9 (CHCH3), 17.2 
(CH3).  
MS (APCI Pos): m/z 228.1 (M+H)+, 210.1 (M+H–H2O)+; HRMS (CI Pos.,TOF): m/z 
228.1400 (228.1388 calcd. for C15H19NO (M+H)+. 
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(S)-N-(1-Hydroxy-1,1-diphenylpropan-2-yl) formamide (155): 
 
To an ice-cooled solution of the amino alcohol 153 (1.8 g, 7.9 mmol) in anhydrous 
CH2Cl2 (10 mL), was added aceticformic anhydride (0.76 mL, 8.63 mmol). The resulting 
clear, brown solution was stirred at ambient temperature for 12 h. The reaction mixture 
was then diluted with CH2Cl2 (10 mL) and the solution was washed with aqueous HCl (0.1 
M, 10 mL). The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexanes 
3/2) to provide the formamide 155 (1.60 g, 79%) as a white foam.  
IR (neat): 3362, 3313, 1647, 1500, 1447, 1379 cm-1.  
1H NMR (300 MHz, CDCl3): Major rotamer δ 7.98-7.93 (br d, 1H, J = 1.5, CHO), 7.52-
7.40 (m, 4H, ArH), 7.35-7.26 (m, 4H, ArH), 7.25-7.16 (m, 2H, ArH), 6.15-6.00 (brd, 1H, 
J = 7.7, NH), 5.26-5.12 (dq, 1H, J = 7.7, CHCH3), 3.14-3.04 (s, 1H, OH), 1.13-1.11 (d, 3H, 
J = 6.6, CH3). Visible peaks for the minor rotamer: 2.75 (br s, 1H, OH), 1.25 (d, 3H, J 
= 6.6, CH3).  
13C NMR (75 MHz, CDCl3): Major rotamer: δ 160.8 (CHO), 144.9 (ArCipso), 144.6 
(ArCipso), 128.43 (ArC), 128.39 (ArC), 127.10 (ArC), 127.06 (ArC), 125.6 (ArC), 125.3 
(ArC), 80.2 (COH), 49.6 (CHCH3), 15.9 (CH3).  
Minor rotamer: δ 164.1 (CHO), 144.2 (ArCipso), 143.8 (ArCipso), 128.6 (ArC), 128.5 
(ArC),  127.4 (ArC), 125.9 (ArC), 125.8 (ArC), 80.0 (C-OH), 54.7 (CHCH3), 17.5 ( CH3). 
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MS (APCI Pos): 238.1 (M–H2O)+; HRMS (CI Pos., TOF): m/z 256.1328 (256.1338 cal. 
for C16H18NO2 (M+H)+. 
(S)-2-(Methylamino)-1,1-diphenylpropan-1-ol (141): 
 
A 100 mL round bottom flask equipped with a reflux condenser, ice bath, magnetic 
stir bar, was charged with lithium aluminium hydride (0.44 g, 11.0 mmol), and THF (10 
mL).  To the stirred suspension was added dropwise a solution of the formamide 155 (1.5 
g, 5.8 mmol) in THF (5 mL). The ice bath was removed when the resulting exothermic 
reaction had diminished and the reaction mixture was heated to reflux for 12 h. The mixture 
was then cooled (< 5 oC) and water (0.2 mL) was added. The mixture was stirred for 15 
min, aqueous sodium hydroxide (2.5 M, 4.6 mL, 11.5 mmol) was added and the stirring 
was continued for an additional 15 min. Water (0.6 mL) was added and the resulting 
mixture was suction filtered to remove the thick white precipitate that was formed. The 
solid residue was washed with THF (2×15 mL) and the combined filtrates were dried 
(Na2SO4) and concentrated under reduced pressure to obtain the crude product as a yellow 
gum. Acid-base purification provided the N-methyl amino alcohol 141 (1.21 g, 85%) as a 
pale yellow gum. 
Mp: 68-70 °C (lit.37 69.8 °C) 
IR (neat): 2980, 2851, 2794, 1489, 1446, 1372, 1179, 1156 cm-1.  
147 
 
1H NMR (300 MHz, CDCl3) δ 7.61-7.58 (m, 2H, ArH), 7.48-7.45 (m, 2H, ArH), 7.33-7.23 
(m, 4H, ArH), 7.25-7.12 (m, 2H, ArH), 3.65 (q, 1H, J = 6.3, CHCH3), 2.34 (s, 3H, NCH3), 
0.96 (d, 3H, J = 6.3, CH3).  
13C NMR (75 MHz, CDCl3) δ 146.7 (ArCipso), 145.0 (ArCipso), 128.5 (ArC), 128.0 (ArC), 
126.9 (ArC), 126.4 (ArC), 126.1 (ArC), 125.8 (ArC), 79.0 (C-OH), 60.5 (CHCH3), 34.2 
(CH3N), 13.9 (CH3).  
MS (APCI Pos): m/z 242.1 (M + H)+; HRMS (CI Pos., TOF): m/z 242.1549 (242.1545 cal. 
for C16H20NO (M+H)+. 
(S)-4,5-Dimethyl-6,6-diphenylmorpholine-2,3-dione (143): 
N
O
O
O
Ph
Ph
 
To a cold (0 oC), stirred solution of (S)-2-(methylamino)-1,1-diphenylpropan-1-ol 
141 (1.0 g, 4.1 mmol) in dichloromethane (20 mL) was added DMAP (0.038 g, 0.031 
mmol). Triethylamine (0.23 mL, 16.4 mmol) was added followed by dropwise addition of 
oxalyl chloride (1.05 mL, 12.4 mmol). The mixture was stirred at 0 ºC for 1 h and then at 
ambient temperature for 4 h. Cold water was added and the mixture was extracted with 
dichloromethane (3 × 30 mL). The combined organic layers were washed with aqueous 
HCl (2 M, 2 × 20 mL), dried (Na2SO4) and concentrated under reduced pressure to give a 
pale yellow oil. Purification of the crude product by flash chromatography on silica gel 
(EtOAc/hexane 7/3) gave 143 (0.52 g, 46%) as a pale yellow foam. 
IR (neat): 1762, 1680, 1189, 1150 cm-1.  
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1H NMR (500 MHz, CDCl3) δ 7.42-7.39 (m, 4H, ArH), 7.37-7.33 (m, 4H, ArH), 7.30-7.26 
(m, 2H, ArH), 4.46 (q, 1H, J = 6.7, CHCH3), 3.13 (s, 3H, NCH3), 1.21 (d, 3H, J = 6.7, 
CH3).  
13C NMR (75 MHz, CDCl3) δ 156.4 (OCO), 153.3 (NCO), 141.4 (ArCipso), 139.5 (ArCipso), 
129.3 (ArC), 128.9 (ArC), 128.7 (ArC), 128.1 (ArC), 125.4 (ArC), 124.6 (ArC), 87.0 
(CCH), 59.0 (CHCH3), 33.9 (NCH3), 15.00 (CH3).  
MS (APCI Pos): m/z 296.1 (M+H)+; HRMS (CI Pos., TOF): m/z 296.1280 (296.1287 calc. 
for C18H18NO3, (M+H)+.  
(5S)-2-Hydroxy-4,5-dimethyl-6,6-diphenyl-2-propylmorpholin-3-one (157): 
N
O
O
Ph
Ph
OH
 
To a suspension of 143 (495 mg, 1.70 mmol) in anhydrous ether (10 mL) at 0 C 
was added propylmagnesium bromide (prepared from Mg (131 mg, 5.40 mmol), and of 1-
bromopropane (460 L, 5.40 mmol) in ether (10 mL) and the mixture was stirred 3 h at 
ambient temperature. Saturated aqueous NH4Cl solution was added, the mixture was stirred 
to dissolve any precipitated solids and was then extracted with ethyl acetate (3×15 mL). 
The combined extracts were dried (Na2SO4) and concentrated. The residue was purified by 
flash chromatography on silica gel (EtOAc/hexane 3/1) to provide 157 (490 mg, 86%) as 
a pale green oil (5:1 mixture of diastereomers). 
IR (neat): 2965, 1650, 1493, 1448, 1128, 1071, 1017 cm-1.  
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1H NMR (300 MHz, CDCl3): Major diastereomer: δ 7.39-7.22 (m, 10H, ArH), 4.30 (q, 
1H, J = 6.5, CHCH3), 3.20 (s, 3H, NCH3), 2.53 (s, 1H, OH), 1.96-1.90 (m, 2H, CH2COH), 
1.85-1.75 (m, 1H, CH2), 1.75-1.65 (m, 1H, CH2), 1.04 (d, 3H, J = 6.5, CH3CH), 1.03 (t, 
3H, J = 7.5, CH2CH3).  
Visible peaks for the minor diastereomer: δ 4.25 (q, 1H, J = 6.6, CHCH3), 3.18 (s, 3H, 
NCH3), 2.88 (s, 1H, OH), 1.17 (d, 3H, J = 6.6, CHCH3), 0.08 (t, 3H, J = 7.4, CH2CH3).  
13C NMR (75 MHz, CDCl3): Major diastereomer: δ 169.4 (CO), 143.7 (ArCipso), 142.5 
(ArCipso), 128.5 (ArC), 128.3 (ArC), 128.1 (ArC), 128.0 (ArC), 127.0 (ArC), 125.3 (ArC), 
96.8 (C-OH), 79.9 (NCH), 59.3 (CHCH3), 43.6 (CH2CH2CH3), 33.9 (NCH3), 16.5 
(CH3CH2), 14.5 (CH2CH3), 14.2 (CH3CH).  
Visible peaks for the minor diastereomer: δ 168.1 (CO), 142.9 (ArCipso), 128.3 (ArC), 
128.2 (ArC), 127.8 (ArC), 127.4 (ArC), 125.6 (ArC), 97.1 (C-OH), 81.5 (NCH), 58.5 
(CHCH3), 39.4 (CH2CH2CH3), 29.7 (NCH3), 15.3 (CH2CH3), 15.0 (CH2CH3), 14.3 
(CHCH3).  
MS (APCI Pos): m/z 322.3 ((M+H–H2O)+; HRMS (CI Pos.,TOF): m/z 340.1925 (340.1913 
cal. for C21H26O3N (M+H)+. 
(2R,5S)-2-Allyl-4,5-dimethyl-6,6-diphenyl-2-propylmorpholin-3-one (158): 
 
To a solution of 157 (0.3 g, 0.8 mmol) in dichloromethane (12 mL) at –78 C was 
added TiCl4 (0.58 mL, 5.30 mmol) followed by allyltrimethylsilane (0.84 mL, 5.30 mmol). 
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The mixture was gradually warmed to room temperature and allowed to stir at this 
temperature for 1 h.  Water was added and the mixture was warmed to ambient temperature. 
The biphase was separated and the aqueous layer was extracted with CH2Cl2 (3×10 mL). 
The combined extracts were dried (Na2SO4) and concentrated. The residue was purified by 
flash chromatography on silica gel (EtOAc/hexane 2/1) to provide 158 (0.172 g, 54%) as 
a colourless gum (3:1 mixture of diastereomers). 
IR (neat): 2964, 1650, 1448, 1142, 1071, 1016 cm-1.  
1H NMR (300 MHz, CDCl3): Major diastereomer:  δ 7.26-7.18 (m, 10H, ArH), 5.93-
5.79 (m, 1H, CH=CH2), 5.02- 4.95 (m, 1H, CH=CH2), 4.93- 4.82 (m, 2H, CH=CH2), 4.24 
(q, 1H, J = 6.5, CHCH3), 3.17 (s, 3H, NCH3), 2.09- 2.01 (dd, 1H, J = 15.0, 8.0, 
CH2CH=CH2), 1.85-1.70 (m, 3H, CH2CH=CH2, CH2CH2CH3), 1.50-1.25 (m, 2H, 
CH2CH3),  0.98 (d, 3H, J = 6.5, CH3CH), 0.93 (t, 3H, J = 7.0, CH2CH3).  
Visible peaks for the minor diastereomer: 5.20-5.15 (m, 1H, CH=CH2), 5.10-5.05 (m, 
1H, CH=CH2), 3.15 (s, 3H, NCH3).  
13C NMR (75 MHz, CDCl3): Major diastereomer: δ 171.4 (CO), 145.3 (ArCipso), 143.9 
(ArCipso), 134.1 (CH=CH2), 128.6 (br, ArC), 128.1 (ArC), 128.08 (ArC), 127.86 (ArC), 
126.8 (ArC), 125.8 (br, ArC), 117.2 (CH=CH2), 80.6 (NCH), 78.9 (C(O)-C-O), 58.8 
(CHCH3), 42.0 (CH=CH2), 40.4 (CH2CH2), 33.9 (NCH3), 17.8 (CH2CH3), 16.1 (CH2CH3), 
14.5 (CHCH3).  
Minor Diastereomer: δ 144.1 (ArCipso), 134.6 (CHCH2), 128.04 (ArC), 127.9 (ArC), 
127.6 (ArC), 126.7 (ArC), 118.0 (ArC), 81.2 (NCH), 78.8 (C(O)-C-O), 43.5 (CH=CH2), 
37.9 (CH2CH2), 33.8 (NCH3), 16.3 (CH2CH3), 15.3 (CH2CH3), 13.7 (CHCH3).  
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MS (APCI Pos): m/z 364.4 (M+H) + HRMS (CI Pos., TOF): m/z 364.2295 (364.2277 calc. 
for C24H30NO2, (M+H)+. 
(2S,5S)-2-Hydroxy-2-isopropyl-4,5-dimethyl-6,6-diphenylmorpholin-3-one (159): 
 
To a suspension of the dione 143 (600 mg, 2.03 mmol) in anhydrous ether (7 mL) 
at 0 °C was added isopropylmagnesium chloride (2.00 M solution in THF, 5.10 mL, 10.1 
mmol) and the mixture was warmed to ambient temperature. The reaction mixture was 
stirred for 5 h at ambient temperature and saturated aqueous NH4Cl solution (4 mL) was 
added. The resulting mixture was extracted with ethyl acetate (3×10 mL) and the combined 
extracts were dried (Na2SO4) and concentrated. Purification of the crude product by flash 
chromatography on silica gel (EtOAc/hexanes 65:35) gave the hemiacetal 159 (590 mg, 
87%) as a white foam (4:1 mixture of diastereomers).  
IR (neat): 3372, 2978, 1649, 1493, 1448, 1017, 1382, 1311, 1242, 1139, 1076, 1018 cm-1. 
1H NMR (300 MHz, CDCl3): Major diastereomer: δ 7.35-7.17 (m, 10H, ArH), 4.29 (q, 
1H, J = 6.6, CHCH3), 3.18 (s, 3H, NCH3), 2.31 (s, 1H, OH), 2.22 (sep, 1H, J = 6.8, 
CH(CH3)2), 1.17 (d, 3H, J = 6.8, CHCH3), 1.08 (d, 3H, J = 6.8, CHCH3), 1.00 (d, 3H, J = 
6.6, CHCH3).  
Minor diastereomer: δ 4.58- 4.56 (q, 1H, J = 6.6, CHCH3), 3.41 (s, 3H, NCH3), 1.26 (d, 
3H, J = 6.6, CHCH3), 1.22 (d, 3H, J = 6.8, CHCH3);  
13C NMR (75 MHz, CDCl3): Major diastereomer: δ 169.2 (CO), 144.1 (ArCipso), 142.8 
(ArCipso), 128.4 (ArC), 128.3 (ArC), 128.2 (ArC), 128.0 (ArC), 127.0 (ArC), 125.4 (ArC), 
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98.5 (C-OH), 79.3 (NCH), 59.1 (CHCH3), 37.8 (CH(CH3)2), 33.91 (N-CH3), 18.0 
(CHCH3), 15.6 (CH(CH3)2), 15.4 (CH(CH3)2).  
Minor diastereomer: δ166.3 (CO), 143.8 (ArCipso), 128.1 (ArC), 127.9 (ArC), 127.8 
(ArC), 127.4 (ArC), 126.8 (ArC), 124.9 (ArC), 95.9 (C-OH), 80.4 (NCH), 58.6 (CHCH3), 
33.85 (N-CH3), 16.2 (CH(CH3)2). 
MS (APCI Pos): m/z 322.3 ((M+H–H2O)+; HRMS (CI Pos., TOF): m/z 339.1842 
(339.1834 cal. for C21H25NO3 (M+), 322.1807 ((M+H– H2O)+. 
(2S,5S)-2-Allyl-2-isopropyl-4,5-dimethyl-6,6-diphenylmorpholin-3-one (160): 
 
To a solution of 159 (0.6 g, 1.7 mmol) in dichloromethane (6 mL) at –78 C was 
added TiCl4 (1.06 mL, 10.6 mmol) followed by allyltrimethylsilane (1.68 mL, 10.6 mmol). 
The mixture was gradually warmed to room temperature and allowed to stir at this 
temperature for 1 h.  Water was added and the mixture was warmed to ambient temperature. 
The biphase was separated and the aqueous layer was extracted with CH2Cl2 (3×10 mL). 
The combined extracts were dried (Na2SO4) and concentrated. The residue was purified by 
flash chromatography on silica (EtOAc/hexane 2/1) to give 160 (369 mg, 58%) as a 
colourless gum. 
IR (neat): 3068, 2978, 2929, 1641, 1490, 1446, 1382, 1312, 1236, 1143, 1075, 1027, 908 
cm-1.  
1H NMR (300 MHz, CDCl3): Major diastereomer: δ 7.29-7.18 (s, 10H, ArH), 5.96-5.85 
(m, 1H, CH=CH2),  4.88-4.83 (m, 1H, CH=CH2), 4.82-4.74 (m, 1H, CH=CH2), 4.25 (q, 
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1H, J = 6.6, CHCH3), 3.18 (s, 3H, NCH3), 2.23 (sep, 1H, J = 6.8, CH(CH3)2), 1.76-1.58 
(m, 2H, CH2CH=CH2), 1.13 (d, 3H, J = 6.8, CHCH3CH), 1.04 (d, 3H, J = 6.8, CHCH3CH), 
0.96 (d, 3H, J = 6.6, CHCH3).  
Visible peaks for the minor diastereomer: δ 5.18-5.05 (m, 2H, CH=CH2CH), 3.16 (s, 
3H, NCH3), 0.91 (d, 3H, J = 6.8, CHCH3), 0.89-0.87 (d, 3H, J = 6.6, CH(CH3)2), 0.61-0.58 
(d, 3H, J = 6.6, CH(CH3)2).  
13C NMR (75 MHz, CDCl3): δ 171.4 (CO), 145.8 (ArCipso), 144.4 (ArCipso), 135.4 
(CH=CH2), 128.1 (ArC), 128.0 (ArC), 127.9 (ArC), 126.7 (ArC), 115.9 (CH=CH2), 82.4 
(C(Ar)2), 78.4 (C-C=O), 58.6 (CHCH3), 41.3 (CH2CH=CH2), 35.3 (CH(CH3)2), 33.7 
(NCH3), 19.2 (CHCH3), 16.4 (CHCH3), 16.3 (CHCH3).  
MS (APCI Pos): m/z 364.1 (M+H)+, 345.3 (M–H2O)+; HRMS (CI Pos., TOF): m/z 
364.2280 (364.2277 cal. for C24H30NO2 (M+H)+. 
(S)-2-Amino-1,1-bis(4-methoxyphenyl)propan-1-ol (154):  
 
A dry 250 mL three-necked round bottom flask, equipped with a reflux condenser, 
magnetic stirring bar and nitrogen gas inlet was charged with magnesium turnings (6.39 g, 
0.26 mol), The flask was fitted with a rubber septum and charged sequentially via syringe 
with diethyl ether (180 mL), 4-bromoanisole (31.60 mL, 251.8 mmol ) and methyl iodide 
(0.05 mL). The rubber septum was replaced with a stopper. Within 5 min, an exothermic 
reaction initiated and the mixture began to reflux spontaneously. The mixture was then 
stirred for an additional 4 h (until all of the magnesium reacted) without external heating 
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or cooling. The resulting solution was then added drop wise to an ice-cooled suspension of 
(S)-alanine methylester hydrochloride 152 (7.00 g, 50.3 mmol) in THF (30 mL) using a 
syringe over a period of 30 min and the mixture was stirred at ambient temperature for 16 
h. A saturated aqueous solution of ammonium chloride (60 mL) was then added, and the 
mixture was stirred vigorously until all of the white precipitate dissolved. The resulting 
solution was extracted with ethyl acetate (3×100 mL). The combined ethyl acetate layers 
were dried (Na2SO4) and concentrated under reduced pressure to provide the crude product 
as a yellow gum. This was dissolved in aqueous HCl (1 M, 10 mL) and the solution was 
extracted with ethyl acetate (2×50 mL). The aqueous layer was cooled (<5 oC), basified 
with sodium hydroxide pellets (pH = 9) and then extracted with ethyl acetate (3×50 mL). 
The combined organic layers were dried (Na2SO4) and concentrated under reduced 
pressure to provide 154 (11.0 g, 88%) as a sticky, yellow solid. 
IR (neat): 2971, 2903, 2836, 1605, 1506, 1243, 1171, 1030 cm-1.  
1H NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J = 8.8, ArH), 7.36 (d, 2H, J = 8.8, ArH), 6.85 
(d, 2H, J = 8.8, ArH), 6.81 (d, 2H, J = 8.8, ArH), 4.03 (q, 1H, J = 6.3, CHCH3), 3.77 (s, 
3H, OCH3), 3.76 (s, 3H, OCH3), 0.94 (d, 3H, J = 6.3, CHCH3).  
13C NMR (75 MHz, CDCl3): δ 158.2 (ArC-OCH3), 158.0 (ArC-OCH3), 139.3 (ArCipso), 
137.4 (ArCipso), 127.1 (ArC), 126.7 (ArC), 113.8 (ArC), 113.3 (ArC), 78.1(C-OH), 55.3 
(OCH3), 55.2 (OCH3), 52.1 (CHCH3), 17.3 (CHCH3).  
MS (APCI Pos): m/z 270.1 ((M+H–H2O)+; HRMS (CI Pos., TOF): m/z 288.1605 (288.1600 
calcd. for C17H22NO3 (M+H)+. 
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(S)-N-(1-Hydroxy-1,1-bis (4-methoxyphenyl)propan-2-yl) formamide (156): 
 
To a cooled (<5 oC) solution of the amino alcohol 154 (2.25 g, 7.84 mmol) in 
anhydrous CH2Cl2 (10 mL), was added acetic formic anhydride (0.75 mL, 8.62 mmol). The 
resulting clear, brown solution was stirred at ambient temperature for 12 h. The reaction 
mixture was then diluted with CH2Cl2 (10 mL) and the solution was washed with aqueous 
HCl (0.1 M, 10 mL). The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexanes, 
3/2) to provide the formamide 156 (1.64 g, 67%) as a white foam. 
IR (neat): 3303, 2991, 2941, 1732, 1651, 1606, 1507, 1454, 1376, 1243, 1175, 1034 cm-1 
1H NMR (500 MHz, CDCl3):  Major rotamer: δ 7.97 (s, 1H, CHO), 7.37 (d, 2H, J = 8.9, 
ArH), 7.32 (d, 2H, J = 8.9, ArH), 5.10 (m, 1H, CHCH3). 3.77 (s, 3H, OCH3), 3.75 (s, 3H, 
OCH3),  1.10 (d, 3H, J = 6.6, CHCH3). 
Visible peaks for the minor rotamer: δ 7.29- 7.28 (d, 2H, J =8.9, ArH), 6.88 (d, 2H, J = 
8.9, ArH), 6.70 (d, 2H, J = 8.9, ArH), 3.79 (s, 3H, OCH3).  
13C NMR (75 MHz, CDCl3): 160.6 (CHO), 158.5 (ArC-OCH3), 137.2 (ArCipso), 137.1 
(ArCipso), 126.8 (ArC), 126.6 (ArC), 113.7 (ArC), 79.8 (NCH), 55.23 (OCH3), 55.20 
(OCH3), 49.6 (CHCH3), 16.1 (CH3).  
MS (APCI Pos): m/z 298.1 ((M+H–H2O)+.  
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(S)-1,1-bis (4-Methoxyphenyl)-2-(methylamino)propan-1-ol (142): 
 
A 100 mL round bottom flask equipped with a reflux condenser, ice bath and 
magnetic stir bar, was charged with lithium aluminium hydride (0.94 g, 24.7 mmol), and 
THF (15 mL).  To the stirred suspension was added drop wise a solution of the formamide 
156 (3.90 g, 12.3 mmol) in THF (20 mL). The ice bath was removed when the resulting 
exothermic reaction had diminished and the reaction mixture was heated to reflux for 12 h. 
The mixture was then cooled (<5 oC) and water (0.5 mL) was added. The mixture was 
stirred for 15 min, aqueous sodium hydroxide (2.5 M, 9.8 mL) was added and the stirring 
was continued for an additional 15 min. Water (1.5 mL) was added and the resulting 
mixture was suction filtered to remove the thick white precipitate that was formed. The 
solid residue was washed with THF (2×15 mL) and the combined filtrates were dried 
(Na2SO4) and concentrated under reduced pressure to obtain the crude product as a yellow 
gum. Acid-base purification provided the N-methyl amino alcohol 142 (3.08 g, 82%) as a 
pale yellow gum. 
IR (neat): 3447, 3381, 2972, 2901, 2835, 1606, 1506, 1451, 1294, 1243, 1169, 1029, 964 
cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.47 (d, 2H, J = 8.8, ArH), 7.35 (d, 2H, J = 8.8, ArH), 6.85 
(d, 2H, J = 8.9, ArH), 6.80 (d, 2H, J = 8.9, ArH), 3.77 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 
3.54 (q, 1H, J = 6.3, CHCH3), 2.36 (s, 3H, NCH3) , 0.96 (d, 3H, J = 6.3, CHCH3).  
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13C NMR (75 MHz, CDCl3): δ 158.3 (ArC-OCH3), 158.0 (ArC-OCH3), 138.8 (ArCipso), 
137.3 (ArCipso), 127.3 (ArC), 127.0 (ArC), 113.7 (ArC), 113.2 (ArC), 78.5 (C-OH), 60.6 
(CHCH3), 55.22 (OCH3), 55.16 (OCH3), 34.1 (NCH3), 13.9 (CH3).  
MS (APCI Pos): m/z 284.1 ((M+H–H2O)+, 302.3 (M+H)+; HRMS (CI Pos., TOF): m/z 
302.1762 (302.1756 calcd. for C18H24NO3 (M+H)+. 
(S)-6,6-Bis(4-methoxyphenyl)-4,5-dimethylmorpholine-2,3-dione (144): 
 
To a stirred solution of the amino alcohol 142 (2.0 g, 6.6 mmol) and DMAP (0.85 
g, 0.69 mmol) in dichloromethane (25 mL) at 0 °C was added triethylamine (1.65 mL, 19.9 
mmol). The mixture was stirred for 10 min and a solution of oxalyl chloride (4.18 mL, 27.9 
mmol) in dichloromethane (5 mL) was added drop wise over a period of 30 min. at 0 °C. 
The mixture was stirred at room temperature for 8 h and water (10 mL) was added. The 
biphase was separated and the dichloromethane layer was washed with water (10 mL), 
dried (Na2SO4) and concentrated. The residue was purified by flash chromatography on 
silica gel (EtOAc/hexane 7/3) to furnish 144 (1.5 g, 65%) as a white solid.  
IR (neat): 2933, 1760, 1687, 1608, 1511, 1251, 1178, 1031 cm-1.  
1H NMR (300 MHz, CDCl3): δ 7.32-7.26 (m, 4H, ArH), 6.88-6.84 (m, 4H, ArH), 4.35 (q, 
1H, J = 6.7, CHCH3), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.14 (s, 3H, NCH3), 1.21 
(d, 3H, J = 6.7, CH3).  
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13C NMR (75 MHz, CDCl3): δ 159.5 (ArC-OCH3), 159.2 (ArC-OCH3), 156.7 (C(O)N), 
153.4 (C(O)O), 133.7 (ArCipso), 132.0 (ArCipso), 126.9 (ArC), 126.1 (ArC), 114.6 (ArC), 
114.1 (ArC), 86.9 (C-O), 59.2 (CHCH3), 55.3 (OCH3), 33.9 (NCH3), 15.0 (CHCH3).  
MS (APCI Pos): m/z 356.1 (M+H)+; HRMS (CI Pos., TOF): m/z 355.1410 (355.1420 calcd. 
for C20H21NO5 (M+)). 
(S)-2-Hydroxy-2-isopropyl-6,6-bis(4-methoxyphenyl)-4,5-dimethylmorpholin-3-one 
(161): 
 
To a suspension of the dione 144 (600 mg, 1.60 mmol) in anhydrous ether (7 mL) 
at 0 °C was added isopropylmagnesium bromide (4.3 mL, 2.0 M solution in THF, 8.4 
mmol) and the mixture was warmed to ambient temperature. The reaction mixture was 
stirred 5 h at ambient temperature and saturated aqueous NH4Cl solution was added. The 
resulting mixture was extracted with ethyl acetate (3×10 mL) and the combined organic 
layers were dried (Na2SO4) and concentrated. Purification of the crude product by flash 
chromatography on silica gel (EtOAc/hexanes 6.5/3.5) provided of the hemiacetal 161 (590 
mg, 88%) as a white foam.  
IR (neat): 2970, 1649, 1605, 1507, 1454, 1301, 1246, 1176, 1020 cm-1.  
1H NMR (500 MHz, CDCl3): Major diastereomer:  δ 7.25-7.15 (br, 2H, ArH), 7.20  (d, 
2H, J = 8.7, ArH), 7.16 (d, 2H, J = 8.7, ArH), 6.82 (d, 2H, J = 8.7, ArH), 6.83-6.81 (br, 
2H, ArH), 4.19 (q, 1H, J = 6.6, CHCH3), 3.78 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.16 (s, 
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3H, NCH3), 2.31 (s, 1H, OH), 2.21 (sep, 1H, J = 6.8, CH(CH3)2), 1.15 (d, 3H, J = 6.8, 
CH(CH3)2), 1.04 (d, 3H, J = 6.8, CH(CH3)2), 0.99 (d, 3H, J = 6.6, CHCH3).  
Visible peaks for the minor diastereomer: δ 7.44 (d, 2H, J = 8.0, ArH), 7.39 (d, 2H, J = 
8.0, ArH), 4.12 (q, 1H,  J = 6.9, CHCH3), 3.79 (s, 3H, OCH3), 3.75 (s, 3H, OCH3),  3.19 
(s, 3H, NCH3).  
13C NMR (75 MHz, CDCl3): Major diastereomer: δ 169.4 (C=O), 159.1 (ArC-OCH3), 
158.4 (ArC-OCH3), 136.7 (ArCipso), 134.8 (ArCipso), 129.5 (ArC), 126.7 (ArC), 113.8 
(ArC), 113.5 (ArC), 98.5 (C-OH), 78.8 (C-O), 59.6 (CHCH3), 55.2 (OCH3), 37.7 (CHCH3), 
33.9 (NCH3), 18.0 (CHCH3), 15.6 (CHCH3), 15.5 (CHCH3). 
Visible peaks for the minor diastereomer: δ 158.3 (ArC-OCH3), 129.3 (ArC), 113.4 
(ArC), 113.3 (ArC), 98.3 (C-OH), 60.4 (CHCH3), 21.1 (CHCH3), 14.2 (CHCH3).  
MS (APCI Pos): m/z 398.1 (M-1), 399.1 (M)+; HRMS (EI Pos., TOF): m/z 399.2052 
(399.2046 calcd. for C23H29NO5 (M+)); HRMS (CI Pos., TOF): m/z 400.2120 (400.2124 
calcd. for C23H30NO5 (M+H)+). 
(2S,5S)-2-Allyl-2-isopropyl-6,6-bis(4-methoxyphenyl)-4,5-dimethylmorpholin-3-one 
(162): 
 
To a solution of the hemiacetal 161 (600 mg, 1.50 mmol) in dichloromethane (10 
mL) at –78 °C was added TiCl4 (0.98 mL, 9.00 mmol) followed by allyltrimethylsilane 
(1.4 mL, 9.0 mmol). The mixture was gradually warmed to –40 °C and stirred at this 
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temperature for 4.5 h. Saturated aqueous NH4Cl (4 mL) was added and the mixture was 
warmed to ambient temperature. Water (5 mL) was added and the mixture was extracted 
with CH2Cl2 (3×15 mL), dried (Na2SO4) and concentrated. The residue was purified by 
flash chromatography on silica (hexanes/ethyl acetate, 3:2) to provide 162 (350 mg, 55%) 
as a white foam.  
IR (neat) 2934, 1641, 1609, 1509, 1442, 1302, 1248, 1174, 1135, 1030 cm-1.  
1H NMR (500 MHz, CDCl3): δ 7.10 (d, 2H, J = 8.6, ArH), 6.82 (br s, 2H, ArH), 6.76-6.75 
(d, 2H, J = 8.8, ArH), 5.97-5.88 (m, 1H, CHCH2), 4.87 (d, 1H, J = 10.3, CH=CH2), 4.80 
(d, 1H, J = 17.7, CH=CH2), 4.17 (q, 1H, J = 6.6, CHCH3), 3.79 (s, 3H, OCH3), 3.77 (s, 3H, 
OCH3), 3.15 (s, 3H, NCH3), 2.23– 2.17 (m, 1H, CH(CH3)2), 1.78-1.74 (dd, 1H, J = 15.0, 
6.5, CH2CH=CH2), 1.66-1.62 (dd, 1H, J = 15.1, 6.5, CH2CH=CH2), 1.11 (d, 1H, J = 6.8, 
CHCH3), 1.03 (d, 1H, J = 6.8, CHCH3), 0.96 (d, 3H, J = 6.6, CHCH3).  
13C NMR (125 MHz, CDCl3) δ 172.0 (C=O), 159.3 (ArC-OCH3), 158.6 (ArC-OCH3), 
138.7 (CH=CH2), 137.0 (ArCipso), 136.0 (ArC), 116.2 (ArC), 113.7 (CH=CH2), 82.5 (C-
(Ar)2), 78.3 (C-C=O), 59.5 (CHCH3), 55.58 (OCH3), 55.56 (OCH3), 41.7 (CH2CH=CH2), 
35.7 (CH(CH3)2 or NCH3), 34.1 (NCH3 or CH(CH3)2, 19.6 (CHCH3), 16.80 (CHCH3), 
16.73 (CHCH3).  
MS (APCI Pos): m/z 424.1 (M+H)+; HRMS (EI Pos., TOF): m/z 423.2410 (423.2410 calcd. 
for C26H33NO4 (M+)). 
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(R)-2-Hydroxy-N-methyl-2-propylpent-4-enamide (120c): 
 
To anhydrous liquid ammonia (distilled over sodium) was added Na (0.05 g, 1.81 
mmol) at –78 C and the mixture was stirred for 15 min. To the resulting blue solution was 
added a solution of 155 (0.11 g, 0.30 mmol) in anhydrous THF (2.5 mL) and the mixture 
was stirred for 1.5 min. A mixture of methanol/water (2:1, 1.5 mL) was added and the 
reaction mixture was brought to ambient temperature and stirred for 30 min to remove 
ammonia. The resulting solution was concentrated under reduced pressure and the residue 
was purified by flash chromatography on silica gel (EtOAc/hexanes, 3/2) to yield 120 c 
(45 mg, 88%) as a white solid. 
IR: 2932, 1730, 1551, 1513, 1247, 1149, 1025 cm-1.  
1H NMR (300 MHz, CDCl3) δ 6.70 (br s, 1H, NH), 5.82-5.68 (m, 1H, CH=CH2), 5.23-
5.14 (m, 2H, CH=CH2), 2.82 (d, 3H, J = 4.9, NHCH3), 2.76- 2.69 (br dd, 1H, J = 13.6, 6.2, 
CH2-CH=CH2), 2.33- 2.25 (dd,  1H, J = 13.6, 8.6, CH2-CH=CH2), 2.30 (s, 1H, OH), 1.88-
1.78 (m, 1H, CH2), 1.57-1.42 (m, 2H, CH2), 1.26-1.20 (m, 1H, CH2), 0.92- 0.88 (t, 3H, J = 
7.2, CH2CH3).  
13C NMR (75 MHz, CDCl3) δ 175.2 (CO), 132.8 (CH=CH2), 120.2 (CH=CH2), 77.3 
(C(OH)CH2), 44.0 (CH2-CH=CH2), 41.5 (CH2CH2), 25.9 (NHCH3), 16.8 (CH2CH3), 14.3 
(CH2CH2).  
MS (EI Pos.): m/z 172.2 (M+H)+.  
[α]D25 = +21.7 (c 1.9, CHCl3); lit.25 [α]D25 = +30 (c 1.9, CHCl3). 
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(S)-2-Hydroxy-2-isopropyl-N-methylpent-4-enamide (120d): 
 
To anhydrous liquid ammonia (distilled over sodium) was added Na (0.07 g, 3.1 
mmol) at –78 C and the mixture was stirred for 15 min. To the resulting blue solution was 
added a solution of 162 (167 mg, 0.39 mmol) in anhydrous THF (2.5 mL) and the mixture 
was stirred for 1.5 min. A mixture of methanol/water (2:1, 1.5 mL) was added and the 
reaction mixture was brought to ambient temperature and stirred for 30 min to remove 
ammonia. The resulting solution was concentrated under reduced pressure and the residue 
was purified by flash chromatography on silica gel (EtOAc/ hexanes, 2/3) to provide 120 
d (60 mg, 90%) as a yellow liquid. 
IR: 3423, 3373, 2968, 1646, 1534, 1409, 1240, 1174, 1004, 915 cm-1.  
1H NMR (300 MHz, CDCl3): Major rotamer: δ 6.62 (s, 1H, NH), 5.74-5.63 (m, 1H, 
CH=CH2), 5.17 (s, 1H, CH=CH2), 5.13 (m, IH, CH=CH2), 2.80 (d, 3H, J = 4.9, NHCH3), 
2.70 (tdd, 1H, J = 13.7, 5.8, 1.2, CH2CH), 2.30-2.23 (dd, 1H, J = 13.7, 9.0, CH=CH2), 2.06 
-1.94 (m, 1H, CH(CH3)2), 0.92 (d, 3H, J = 6.9, CH(CH3)2), 0.87 (d,  3H, J = 6.9, CH(CH3)2).  
Visible peaks for minor rotamer: 2.82 (s, 3H, NHCH3), 0.88 (d, 3H, J = 5.9, CHCH3), 
0.82 (d, 3H, J = 6.8, CH3CH).  
13C NMR (75 MHz, CDCl3): Major rotamer: δ 175.2 (CO), 133.3 (CH=CH2), 119.8 
(CH=CH2), 79.6 (C-OH), 41.7 (CH2CH), 35.0 (CH(CH3)2), 25.8 (NHCH3), 17.45 
(CHCH3), 16.1 (CHCH3).  
Visible peaks for minor rotamer: 175.6 (CO), 17.40 (CHCH3).  
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MS (APCI Pos): m/z 172.2 (M+H)+. 
 [α]D25 = + 9.6 (c 1.6, CHCl3); lit.25 [α]D25 = + 9.0 (c 1.6, CHCl3)  
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3.6 Selected 1H and 13C NMR spectra 
167 
 
 
 
 
153 
CDCl3, 300 MHz 
 
153 
CDCl3, 75 MHz 
168 
 
 
 
 
 
155 
CDCl3, 300 MHz 
 
155 
CDCl3, 75 MHz 
169 
 
 
 
 
141 
CDCl3, 300 MHz 
 
141 
CDCl3, 75 MHz 
170 
 
 
 
 
 
 
143 
CDCl3, 500 MHz 
 
143 
CDCl3, 75 MHz 
171 
 
 
 
 
 
157 
CDCl3, 300 MHz 
 
157 
CDCl3, 75 MHz 
172 
 
 
 
 
 
 
158 
CDCl3, 300 MHz 
 
158 
CDCl3, 75 MHz 
173 
 
 
 
 
159 
CDCl3, 300 MHz 
 
159 
CDCl3, 75 MHz 
174 
 
 
 
 
 
 
160 
CDCl3, 300 MHz 
 
160 
CDCl3, 75 MHz 
175 
 
 
 
 
154 
CDCl3, 500 MHz 
 
154 
CDCl3, 75 MHz 
176 
 
 
 
156 
CDCl3, 500 MHz 
 
156 
CDCl3, 75 MHz 
177 
 
 
 
 
 
142 
CDCl3, 300 MHz 
142 
CDCl3, 75 MHz 
 
178 
 
 
 
 
144 
CDCl3, 300 MHz 
144 
CDCl3, 75 MHz 
 
179 
 
 
 
 
161 
CDCl3, 300 MHz 
 
161 
CDCl3, 75 MHz 
180 
 
 
 
162 
CDCl3, 500 MHz 
 
162 
CDCl3, 75 MHz 
181 
 
 
 
 
120d 
CDCl3, 300 MHz 
 
120d 
CDCl3, 75 MHz 
182 
 
 
 
 
 
120c 
CDCl3, 300 MHz 
 
 
120c 
CDCl3, 300 MHz 
183 
 
Chapter 4 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
184 
 
4.1 Summary of the thesis 
In Chapters 1 and 2 of this thesis, the application of α-hydroxy acid derivatives 
toward the synthesis of (−)-aphanorphine and clauslactone S is demonstrated. Chapter 3 
focuses on the investigation of asymmetric allylation of morpholinones derived from chiral 
amino alcohols for the synthesis of α-hydroxy acid derivatives. This methodology, in turn, 
can be utilized as a substitute for the asymmetric allylation of ephedrine-derived 
morpholinones. 
 In Chapter 1, the synthesis of (+)-8-O-methylaphanorphine (91% ee) is described 
using the readily available α-hydroxy amide 4 (Scheme 4.1) as a chiral starting material. 
The synthesis was accomplished in 10 steps and 7.1% overall yield. This constituted a 
formal synthesis of (−)-aphanorphine (91% ee). 
 The α-hydroxy amide 4 (92% ee), prepared from an ephedrine-derived 
morpholinone 2 (Scheme 4.1), was used as a chiral starting material. 
 
Scheme 4.1 
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 Hydrolysis of amide 4 to the corresponding acid 5 followed by a cross-metathesis reaction 
provided 6 (Scheme 4.2). Amidation using methoxyamine hydrochloride provided the N-
methoxyamide 7. The amide 7 was treated with bis(trifluoracetoxy)iodobenzene1 and the 
product was hydrolyzed to provide the hydroxypyrrolidine 8 as a 5:1 mixture of 
diastereomers. The selectivity for the cyclization step was confirmed by the reductive 
removal of the hydroxy group in 8, by the treatment with Et3SiH in trifluoroacetic acid, 
which provided the pyrrolidinone 9 as a single diastereomer. This confirmed that the 
lactamization reaction is highly stereoselective. Cleavage of the N-O Bond in 9 using 
Mo(CO)6 followed by reduction of the amide provided the key pyrrolidine intermediate 10. 
N-Formylation of 10 followed by Friedel-Crafts cyclization provided the tricyclic 
intermediate 11, which has all the structural elements of aphanorphine. Reduction of the 
formyl group in 11 using LiAlH4 provided (+)-8-O-methylaphanorphine 12 (Scheme 4.2). 
Since the conversion of 11 to (−)-aphanorphine (13) by O-demethylation using BBr3 is 
known,2 the formal synthesis of (−)-aphanorphine is achieved. 
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Scheme 4.2 
In the second project, the α-hydroxy amide 4 was employed in synthetic studies of 
clauslactone S. The synthetic strategy was designed as the assembly of three components; 
the α-hydroxy amide 4, the bromodiene 20 and the coumarin 23. The α-hydroxy amide 4 
was obtained from the methodology developed in the Pansare lab as explained earlier 
(Scheme 4.1).3 The bromodiene 20 was prepared from pyruvaldehyde dimethyl acetal 15 
as the starting material.4 Treatment of 15 with the anion generated from 
triethylphosphonoacetate 14 provided the ester 16. Removal of the acetal protection by 
treatment with 3 M HCl provided 17. Wittig reaction of 17 provided the diene-ester 18. 
The treatment of 18 with LiAlH4 followed by bromination of the allylic alcohol 19 with 
PBr3 provided the bromodiene 20 (Scheme 4.3).  
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Scheme 4.3 
The synthesis of coumarin 23 started with the selective methylation of pyrogallol 
215 by  treatment with Li2CO3 and MeI to provide 22. Treatment of 22 with H2SO4 and 
malic acid furnished the coumarin 23 (Scheme 4.4).6 
 
Scheme 4.4 
Treatment of coumarin 23 with Na2CO3 and the bromodiene 20 provided the ether 
24. A cross-metathesis reaction between 4 and 24 provided the amide 25 (Scheme 4.5) 
which is a potential intermediate to clauslactone S. 
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Scheme 4.5 
In the third project, synthesis of α-hydroxy acid derivatives is investigated using 
morpholinediones obtained from chiral amino alcohols 26-30, Figure 4.1.7 This approach 
was aimed at finding a substitute to the ephedrine-derived morpholinedione. Five different 
chiral amino alcohols 26-30 were investigated. 
 
Figure 4.1 Chiral amino alcohols investigated as a substitute for ephedrine. 
 Out of the five amino alcohols, only the morpholinediones derived from amino 
alcohols 27 and 28 afforded good stereoselectivity in the allylation step. These amino 
alcohols were prepared from the (S)-alanine methyl ester hydrochloride 31. Treatment of 
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31 with an appropriate Grignard reagent provided the amino alcohols 32 and 33 (Scheme 
4.6). N-Formylation with acetic formic anhydride followed by reduction provided the 
amino alcohols 27 and 28.  
Scheme 4.6 
Reaction of 27 and 28 with oxalyl chloride furnished the morpholinediones 34 and 
35 (Scheme 4.7), which upon treatment with propylmagnesium bromide and 
isopropylmagnesium bromide provided the respective hemiacetals (36-38, Scheme 4.7), all 
as 4:1 mixtures of diastereomers. Allylation of these hemiacetals provided the dialkyl 
morpholines 39 (5:1 dr), 40 (9:1 dr) and 41 (single diastereomer, Scheme 4.7).  
 
Scheme 4.7 
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 After several attempts to hydrolyze either the amide or the ether functionality in the 
morpholinones 39, 40 and 41 were unsuccessful, the dissolving metal reduction of these 
morpholinones was attempted. This cleanly generated the α-hydroxy amides 42 and 43. 
The newly generated stereocenter in the morpholinones 39-41 was assigned as R by 
comparison of the sign of optical rotation for the amides 42 and 43 (Scheme 4.8) with that 
previously observed3a for these amides obtained from the ephedrine-derived morpholinone 
2, since in the earlier study, these amides have been converted to known α-hydroxy acids. 
   
Scheme 4.8 
 The morpholinediones 34 and 35 have thus provided an alternative to the 
corresponding ephedrine-derived morpholinedione. Even though the attempts to recover 
the amino alcohols 27 and 28 were unsuccessful, they can certainly be used as substitutes 
for 1R,2S-ephedrine in the synthesis of α-hydroxy acid derivatives. 
4.2 Future work: 
The synthesis of an N-methoxypyrrolidinone 9 as a precursor to the functionalized 
pyrrolidine motif in aphanorphine 13 has provided a promising methodology for the 
synthesis of several substituted N-methylpyrrolidinone natural products8 and related motifs 
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in bioactive molecules.9 The present study could potentially provide methodology for their 
synthesis.  
The clauslactone S (46) synthesis can be investigated further from the intermediate 
25. The successful halolactonization of 25 would furnish 44, which is the core structure of 
clauslactone S 46. If successful, the dehalogenation of 44 will provide 45. Epoxidation of 
45 should provide clauslactone S or its stereoisomer (Scheme 4.9). The stereochemical 
outcomes of the lactonization and the epoxidation reactions are crucial. 
Scheme 4.9 
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